The Effect of Arsenic on Type 2 Diabetes and Inflammation by Penta, Kayla
University of South Carolina
Scholar Commons
Theses and Dissertations
2016
The Effect of Arsenic on Type 2 Diabetes and
Inflammation
Kayla Penta
University of South Carolina
Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Other Medical Sciences Commons
This Open Access Dissertation is brought to you by Scholar Commons. It has been accepted for inclusion in Theses and Dissertations by an authorized
administrator of Scholar Commons. For more information, please contact dillarda@mailbox.sc.edu.
Recommended Citation
Penta, K.(2016). The Effect of Arsenic on Type 2 Diabetes and Inflammation. (Doctoral dissertation). Retrieved from
https://scholarcommons.sc.edu/etd/3979
The Effect of Arsenic on Type 2 Diabetes and Inflammation 
 
by 
 
Kayla Penta 
 
Bachelor of Science 
Utica College, 2011 
 
 
 
 
Submitted in Partial Fulfillment of the Requirements 
 
For the Degree of Doctor of Philosophy in 
 
Biomedical Science 
 
School of Medicine 
 
University of South Carolina 
 
2016 
 
Accepted by: 
 
Jennifer Nyland, Major Professor 
 
Lucia Pirisi-Creek, Committee Member 
 
Wayne Carver, Committee Member  
 
Angela Murphy, Committee Member 
 
David Volz, Committee Member 
 
Cheryl L. Addy, Vice Provost and Dean of the Graduate School
ii 
© Copyright by Kayla Penta, 2016 
All Rights Reserved.
  
 
iii 
Dedication 
I would like to dedicate this project to my family. First, my mom for her 
unconditional love and support and being the strongest woman I know. Next, my 
grandparents who were the foundation for who I have become today with their 
unwavering encouragement. Finally, my husband – who has been my rock during this 
entire process. I would not have made it this far without all of your love and support.  
  
iv 
Acknowledgements 
 Over the past 5 years, numerous individuals have helped me succeed both inside 
and outside of the lab. I would like to thank the various individuals in and next door to 
the Nyland lab: Anne for your help and laughter, and Devon and the Gomez lab for 
middle of the day chats to help pass the time. I would also like to thank my committee for 
all of their input in the development of this project and the encouragement along the way.  
I would like to acknowledge my South Carolina family for keeping me grounded 
and reminding me that it is necessary to have fun to maintain mental stability. You guys 
have kept me sane in some of the most trying times in my life. I would also like to thank 
Megan for being a constant source of support and love, showing that even at 1000 miles 
away what true friendship means. 
 To my family, the ones that have loved and supported me always – I wouldn’t be 
where I am today without you. I would especially like to thank my husband, who as a 
non-scientist has had to listen to me talk about my project and give practice talks, and 
now probably knows almost as much about this project as I do. I am so grateful for you. 
 Finally, I would like to thank Jennifer Nyland. Not only have you been an 
excellent mentor, but you have also been a wonderful friend. Without your patience and 
support I would not have been able to complete this degree (or that half marathon!). 
  
v 
Abstract 
 Arsenic, a ubiquitous environmental contaminant, has been shown to cause a 
number of health effects. At high concentrations the inorganic form is a well-known 
toxin, but at lower concentrations the effects range from various cancers, to 
cardiovascular disease and type 2 diabetes. At higher concentrations of arsenic (500-
1000µg/L) there have been epidemiological studies conducted demonstrating an 
increased risk in the development of type 2 diabetes with this exposure. At lower levels 
of arsenic exposure (<500 µg/L) the epidemiological results are inconclusive. Arsenic is 
also an immunotoxicant, meaning that it will cause changes in the immune response. The 
changes in the immune response will vary depending on a number of variables, including 
amount of arsenic exposure, forms of exposure and route of exposure. We wanted to 
determine if arsenic could modulate the immune system, and if this change could lead to 
an increase in susceptibility to type 2 diabetes development. We chose to examine this in 
C57BL/6 and db/+ mice – two non-susceptible strains. After 8 weeks (4 weeks old to 12 
weeks old) of low dose inorganic arsenic exposure (50 µg/kg or 500 µg/kg) we evaluated 
changes in body composition, glucose tolerance and immune response. We saw that there 
were differences based on sex, genotype and treatment group present after the 8-week 
treatment period in body composition, while there were minimal changes in glucose 
tolerance. Finally, the immune response showed great variability depending on sex, 
genotype and treatment group. This project has demonstrated that while we are trying to 
compare differences in in vivo and epidemiological studies to find a link between arsenic 
vi 
and type 2 diabetes, there may be deeper levels of complications based on individual 
variability to arsenic exposure.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
Table of Contents 
Dedication .......................................................................................................................... iii 
Acknowledgements ............................................................................................................ iv 
Abstract ................................................................................................................................v 
List of Tables ................................................................................................................... viii 
List of Figures .................................................................................................................... ix 
Chapter 1: Introduction ........................................................................................................1 
Chapter 2: Arsenic and Type 2 Diabetes in C57BL/6 Mice ..............................................32 
Chapter 3: Arsenic and Inflammation ................................................................................65 
Chapter 4: Arsenic and Macrophages ................................................................................88 
Chapter 5: Conclusions and Future Directions ................................................................101 
References ........................................................................................................................112 
  
viii 
List of Tables 
Table 1.1 Summary of Studies Examining Arsenic Exposure in Humans ........................24 
Table 1.2 Summary of in Vivo Studies Examining Arsenic and Type 2 Diabetes ............27 
Table 2.1 Real-time PCR Primer List ................................................................................48 
Table 3.1 Real-time PCR Primer List ................................................................................75 
Table 4.1 Real-time PCR Primer List ................................................................................95 
Table 5.1 Summary of Genotypic Differences in Body Composition .............................104 
Table 5.2 Summary of Genotypic Differences in Systemic Cytokines ...........................105 
Table 5.3 Summary of Genotypic Differences in Immune-Related Gene Expression ....106 
Table 5.4 Summary of Genotypic Differences in Organ Triglycerides ...........................107 
Table 5.5 Summary of Arsenic Effects on Body Composition .......................................108 
Table 5.6 Summary of Arsenic Effects on Organ Triglycerides .....................................109 
Table 5.7 Summary of Arsenic Effects on Cytokines ......................................................110 
Table 5.8 Summary of Arsenic Effects on Immune-Related Gene Expression ...............111 
  
ix 
List of Figures 
Figure 1.1 Urinary inorganic arsenic metabolites ..............................................................29 
Figure 1.2 Summary of arsenic exposure by country ........................................................30 
Figure 1.3 Range of in Vivo exposure compared to human exposure. ..............................31 
Figure 2.1 Experimental layout..........................................................................................49 
Figure 2.2 Change in weight in male wild-type and heterozygotes after 8 weeks of  
arsenic exposure .................................................................................................................50 
 
Figure 2.3 Change in weight in female wild-type and heterozygotes after 8 weeks of  
arsenic exposure .................................................................................................................51 
Figure 2.4 Mean change in body composition in males ....................................................52 
Figure 2.5 Mean change in body composition in females .................................................53 
Figure 2.6 Male oral glucose tolerance test (OGTT) curves .............................................54 
Figure 2.7 Changes in male glucose tolerance ...................................................................55 
Figure 2.8 Female oral glucose tolerance test (OGTT) curves ..........................................56 
Figure 2.9 Changes in female glucose tolerance ...............................................................57 
Figure 2.10 Reproductive adipose tissue histology ...........................................................58 
Figure 2.11 Arsenic does not significantly alter male reproductive adipose tissue  
histology .............................................................................................................................59 
 
Figure 2.12 Arsenic does not significantly alter female reproductive adipose tissue  
histology .............................................................................................................................60 
Figure 2.13 Arsenic significantly increases leptin expression in male heterozygote 
 reproductive adipose tissue ...............................................................................................61 
Figure 2.14 Arsenic significantly increases leptin expression in female wild-type  
reproductive adipose tissue. ...............................................................................................62
x 
Figure 2.15 No differences present in male organ triglycerides. .......................................63 
Figure 2.16 Female heterozygote controls have higher levels of liver and muscle  
triglycerides compared to wild-type controls. ...................................................................64 
Figure 3.1 Arsenic does not significantly after change in fat mass ...................................76 
Figure 3.2 Arsenic has no effect on serum IL-6 levels ......................................................77 
Figure 3.3 Arsenic reduces IFN-γ in spleen of male heterozygotes ..................................78 
Figure 3.4 Increase in arsenic exposure does not affect IFN-γ in male heterozygotes ......79 
Figure 3.5 Arsenic exposure increases IL-1β and IFN-γ in wild-type females .................80 
Figure 3.6 Increase in arsenic exposure affects female heterozygote spleen  
cytokines ............................................................................................................................81 
Figure 3.7 Arsenic exposure does not affect adipose tissue cytokine expression in  
males ................................................................................................................................. 82 
Figure 3.8 Arsenic exposure does not affect adipose tissue cytokine expression in  
females ...............................................................................................................................83 
Figure 3.9 Increase in arsenic exposure affects macrophage gene expression in male 
heterozygote spleens ..........................................................................................................84 
 
Figure 3.10 Arsenic exposure does not affect spleen cytokine expression in females ......85 
Figure 3.11 Arsenic exposure does not affect male macrophage gene expression in  
the liver ..............................................................................................................................86 
Figure 3.12 Arsenic exposure does not affect female macrophage gene expression in  
the liver  .............................................................................................................................87 
Figure 4.1 Raw 264.7 macrophage cell viability after arsenic exposure ...........................96 
Figure 4.2 Short term arsenic exposure has no effect on macrophage cytokine expression 
in low glucose environment ...............................................................................................97 
Figure 4.3 Short term arsenic exposure suppresses macrophage IL-10 expression in 
high glucose environment ..................................................................................................98 
Figure 4.4 Long term arsenic exposure has no effect on macrophage cytokine expression  
in low glucose environment ...............................................................................................99 
xi 
Figure 4.5 Long term arsenic exposure has no effect on macrophage cytokine expression  
in high glucose .................................................................................................................100
 1 
Chapter 1 - Introduction 
1.1 Arsenic 
Arsenic is a ubiquitous element found in the earth’s crust that exists in organic 
and inorganic forms. Unlike other elements, organic arsenic is currently believed to have 
little impact on health, whereas inorganic arsenic is a known toxin. Typical arsenic 
exposure is about 50 µg/day, with about 3.5 µg/day coming from inorganic sources 
(ATSDR, 2013). Organic arsenic includes monomethylarsenous acid (MMA) and 
dimethylarsinous acid (DMA), which are the main forms of arsenic excreted by humans. 
Inorganic arsenic (iAs) is found in the pentavalent form iAs(V) or trivalent form iAs(III), 
with the trivalent being the most toxic form humans are exposed to (Jomova et al., 2011). 
1.2 Arsenic exposure: synthetic sources 
We are exposed to arsenic through both natural and synthetic routes. Arsenic has 
been used in medicine to treat a number of ailments including anemia, asthma, cholera 
and syphilis giving it the nickname ‘Therapeutic Mule’ (Jolliffe, 1993; Przygoda, 
Feldmann, & Cullen, 2001). To treat these ailments, several arsenic-containing solutions 
have been used, including Donavan’s Solution (AsI3), de Valagin’s solution (AsCl3) and 
Fowler’s Solution (1% potassium arsenite) until more recent and less toxic medical 
advances were made (Przygoda et al., 2001; Scheindlin, 2005). Fowler’s Solution, which 
is 1% potassium arsenite, was also used as an alternative to quinine for the treatment of 
malaria (Scheindlin, 2005). More recently, arsenic has returned to use in medicine to treat 
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Acute Promyelocytic Leukemia (APL) in the form of Trisenox (Scheindlin, 2005). APL 
has a very high relapse rate, and FDA-approved Trisenox is meant for these patients 
(Scheindlin, 2005). After treatment with Trisenox, 70% of previously relapsed patients 
were able to achieve complete remission (Scheindlin, 2005). In vitro, Chen et al. 
demonstrated that arsenic trioxide induces apoptosis in the NB4 cell line, which gives a 
potential mechanism for this treatment (G.-Q. Chen et al., 2003). However, future work is 
still required to determine whether arsenic trioxide is a treatment option for other cancers. 
Arsenic-containing compounds have also been used in industry as pesticides and 
preservatives (Mandal & Suzuki, 2002). Chromated copper arsenate, or CCA, is the most 
widely used wood preservative in the world and is used to create pressure treated wood 
(ATSDR, 2013). While not allowed for residential use since 2003, CCA treated wood is 
still used for nonresidential purposes, including utility poles (Hughes, Beck, Chen, Lewis, 
& Thomas, 2011). However, with the ban in place it is currently unknown how CCA-
treated wood contributes to total arsenic exposure (ATSDR, 2013). 
In agriculture, arsenic compounds have been used in cotton fields and orchards 
(Hughes et al., 2011). Lead arsenate was used in apple orchards until the 1960’s, when 
health effects in orchard workers came into question (Hughes, 2002). While lead arsenate 
is no longer used in agriculture, millions of acres of land are still contaminated with the 
pesticide and can potentially impact the health of individuals living on or near this land 
(Hughes et al., 2011) While inorganic arsenic can no longer be used in this capacity, 
organic arsenic is still widely used on cotton (ATSDR, 2013). In industry, individuals 
working in smelters are exposed to high levels of arsenic via inhalation. These 
individuals are subjected to OSHA limits of up to 10 µg/m3 arsenic exposure, which is 
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orders of magnitude higher than normal daily exposure (ATSDR, 2013). The greatest 
health risk posed to these individuals is respiratory cancer. 
1.3 Arsenic exposure: natural sources 
Exposure to arsenic can occur naturally through contaminated soil, air and 
water/food. Arsenic in the soil is typically in the inorganic form, with exposures in the 
range of 0.1-40 mg/kg and average of 3-6 mg/kg (ATSDR, 2013; Mandal & Suzuki, 
2002). This can differ greatly based on location, depending on the proximity to 
agriculture, smelteries and arsenic rich soil deposits (Hughes et al., 2011).Typically, 
arsenic in the soil does not cause a major problem unless the soil is being consumed. 
However, arsenic in the soil becomes an issue when arsenic-rich deposits are the sites of 
wells and water runoff into drinking water sources. 
Humans are exposed to 1x10-3 to 2 µg/m3 inorganic arsenic from air sources, but 
this can also vary based on location, weather, and industry presence (ATSDR, 2013). The 
normal exposure in an unpolluted area is 0.04-0.09 µg/day (Mandal & Suzuki, 2002). 
Arsenic exposure from air can also occur in certain work environments, like smelteries. 
In these locations, OSHA limits have been established at 10 µg/m3, which is still orders 
of magnitude higher than normal daily exposure (ATSDR, 2013). The most common 
health concern for arsenic inhalation exposure is respiratory cancer. No other cancers 
have been attributed to air exposure to arsenic which could be expected as inhalational 
exposure also tends to begin later in life, unlike other exposures like through food and 
water, which can be lifelong (Enterline, Day, & Marsh, 1995). 
Food is the primary route of exposure to organic arsenic as well as high levels of 
inorganic arsenic. The range of exposure from contaminated food is 20-140 ppb, which is 
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a combination of both inorganic and organic species (ATSDR, 2013). Seafood 
consumption is associated with increased levels or organic arsenic exposure, including 
arsenobetaine and arsenocholine, but has not been shown to be associated with 
carcinogenicity (Borak & Hosgood, 2007). Inorganic arsenic in food typically is highest 
in chicken, rice, and apples, and there are few to no regulations in place to limit the 
concentrations people are exposed to (Navas-Acien & Nachman, 2013). Apples and apple 
juice are susceptible to arsenic contamination because, while arsenic has been banned for 
use as a pesticide, persistent remnants in orchard soils from previous use are rapidly 
taken up by these fruit trees (D. Wilson, Hooper, & Shi, 2012). In a study surveying the 
amount of arsenic and lead in common grocery store apple juice brands, the range of 
arsenic was 3.5-24.8 µg/L, the upper range of which is above the acceptable range of 
arsenic in public drinking water. Rice can accumulate arsenic if it is grown in areas with 
high arsenic in the soil or if it is cooked in water with high arsenic contamination  
According to the Consumer Report, levels of inorganic arsenic per serving in rice and 
cereals can range from 1.3-9.6 ppb (Consumer, November, Reports, Agency, & York, 
2012). This is especially dangerous as rice is frequently used in children’s cereal and 
snacks where multiple servings are consumed daily. The health impacts from consuming 
arsenic in food are the same as those from other exposure sources, including cancer, 
cardiovascular disease (CVD) and possibly type 2 diabetes (Davis et al., 2012). 
Arsenic in drinking water has been a part of major regulatory changes in the past 
decades. In the United States, arsenic levels in public drinking water have been regulated 
by the Environmental Protection Agency (EPA), with a reduction from 50 µg/L  to 10 
µg/L  occurring in 2001 because of its carcinogenicity (ATSDR, 2013). However, the 
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range of arsenic exposure in drinking water in the United States is vast, from 0-10 µg/L 
in public drinking water to 800 µg/L in private wells. In other countries such as 
Bangladesh and Taiwan, the concentration of arsenic in drinking water can be well over 
1000 µg/L. Arsenic at the levels in Bangladesh and Taiwan has contributed to the 
development of skin lesions (arsenicosis) and a number of cancers, including skin, lung, 
kidney bladder and liver (ATSDR, 2013); however, in the United States, a study found no 
clear association between drinking water levels of ~100 µg/L and bladder cancer 
(Steinmaus, Yuan, Bates, & Smith, 2003). 
 Besides cancer, high levels of arsenic have been attributed to a number of chronic 
diseases. Argos et al. demonstrated in a range of arsenic exposures (0.1-864 µg/L) 
approximately 22% of deaths associated with chronic disease could be attributed to 
arsenic exposure greater than 10 µg/L drinking water in Bangladesh (2010). This study 
used repeated measurements of total arsenic in urine over time in individuals, and thus 
were able to demonstrate that decreasing arsenic exposure for a short period of time did 
not reduce individual risks for disease. Sohel et al.  examined non-accidental mortality in 
Bangladesh caused by arsenic exposure and the increase for non-accidental death was 
noted even at the lowest levels of exposure (10-49 µg/L) (2009). There was also an 
increase in death from arsenic associated cancer, CVD, and infection in this population.  
  Finally, a number of epidemiological studies have been conducted examining the 
association between arsenic and type 2 diabetes. In areas such as Bangladesh and Taiwan, 
where arsenic levels in drinking water are high, there have been a number of studies 
demonstrating a positive correlation between arsenic exposure and type 2 diabetes risk 
(Nabi, Rahman, & Islam, 2005; M. Rahman, Tondel, Ahmad, & Axelson, 1998; Tsai, 
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Wang, & Ko, 1999; C.-H. Tseng, Chong, Heng, Tseng, & Tai, 2000; S. L. Wang et al., 
2003, 2007). At lower exposures, for example in the United States where public drinking 
water is heavily regulated, the literature is mixed; several studies that have found a 
correlation between arsenic exposure and type 2 diabetes (Kuo et al., 2015; Lewis, 
Southwick, Ouellet-Hellstrom, Rench, & Calderon, 1999; Meliker, Wahl, Cameron, & 
Nriagu, 2007; Navas-Acien, 2008), while several other studies have found a weak 
correlation between arsenic and type 2 diabetes (Gribble et al., 2012; James et al., 2013; 
N. H. Kim et al., 2013) or no correlation at all (Steinmaus, Yuan, Liaw, & Smith, 2009; 
Zierold, Knobeloch, & Anderson, 2004). Unfortunately, because of the wide range of 
variables between studies, no common results have been produced. These 
epidemiological studies, along with in vivo and in vitro studies attempting to find a link 
between arsenic and type 2 diabetes will be reviewed later in this section. 
1.4 Arsenic metabolism  
The first step of arsenic metabolism occurs in the blood. Absorbed iAs(V) is 
rapidly reduced to iAs(III) at least partially in the blood, from where it is distributed to 
tissues and taken up by cells (ATSDR, 2013). The primary source of arsenic methylation 
occurs in the liver; however, a couple of different theories exist to fully explain the 
methylation of inorganic to organic arsenic. Methylation can occur through the classical 
pathway [As(V)As(III) MMA(V)MMA(III)DMA(V)DMA(III)] which is 
catalyzed solely by Arsenic (III) methyltransferase (As3MT) (Thomas et al., 2009).  
Alternatively,  iAs(III) is conjugated to glutathione (GSH), forming several 
arsenic:glutathione intermediates, however the end results are the same (Kumagai & 
Sumi, 2007). Reviewed by Hughes et al., a number of early experiments helped solidify 
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the function and location of S-adenosylmethionine (SAM) and GSH in the methylation of 
arsenic in the liver (Hughes et al., 2011). Healy et al. examined arsenite 
methyltransferase activity in B6C3F1 mice exposed to 0, 25 or 2500 µg/L  arsenic for 
either 32 or 91 days in the liver, testis, kidney and lung (Healy, Casarez, Ayala-Fierro, & 
Aposhian, 1998). They found that the methyltransferase activity varied based on tissue, 
with the testes having the highest level of activity, followed by kidney, liver, and lung, 
respectively, independent of time or concentration of arsenic exposure. 
The final step of arsenic metabolism is either storage in body tissues or excretion. 
Small quantities of arsenic are stored in body tissues along with keratin-rich tissues 
including hair and nails (Weir, 2002). The majority of arsenic is excreted in urine within 
3 days, however a small percentage is excreted in breast milk (M Vahter, 2008) and/or 
feces (Mandal & Suzuki, 2002). General proportions of urinary arsenic metabolites are 
40-75% DMA, 20-25% iAs and 15-25% MMA as demonstrated in Figure 1.1, however a 
number of variables will alter these amounts including exposure time, dose, route of 
exposure, and arsenic species; sex and age of the individual (ATSDR 2013). Calderon et 
al. examined changes in arsenic metabolism over a five-day period in a cohort consisting 
primarily of members of the Church of Jesus Christ of Latter-Day Saints (1999). Day-to-
day variation in arsenic excretion was low and no sex differences were reported, but they 
did find differences in arsenic excretion based on age. This can be compared to the study 
by Concha et al.  that examined blood and urine arsenic levels in children and women in 
three villages in northern Argentina (1998). Blood arsenic levels were 10x higher in both 
women and children living in exposed villages (~200 µg/L in water) compared to 
unexposed villages (1 µg/L). Urine arsenic levels were 30x higher in both women and 
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children in the exposed area. Differences were noted in one of the villages where children 
had a higher percentage of iAs and women had a much higher percentage of DMA, but 
MMA was similar. These differences between adults and children could be due to 
methylation deficiency, which will lead to age differences in arsenic metabolism 
 While the majority of studies have focused on MMA(V), Aposhian et al (2000) 
found a dose-response relationship for arsenic in drinking water and urinary MMA(III). 
MMA(III) is more toxic than inorganic arsenite, demonstrating that the methylation step 
may not be a detoxification process of iAs. MMA(V) reductase is a rate-limiting enzyme 
of the inorganic arsenite biotransformation pathway. When MMA(V) reaches critical 
levels in the cell, it will be converted to MMA(III), so higher levels of exposure will have 
higher levels of MMA(III) (Aposhian et al., 2000). This leaves a new variable for 
epidemiological studies to consider in the analysis of urinary arsenic metabolites. 
1.5 Mechanisms of arsenic 
There are a number of proposed mechanisms for arsenic toxicity, including 
enzyme inhibition, generation of reactive oxygen species (ROS) and epigenetic 
mechanisms (X. Wu et al., 2016).  While pentavalent arsenic is thought to be less toxic, 
possible mechanisms include replacing phosphate in essential biochemical reactions (X. 
Wu et al., 2016). It can replace glucose-6-phosphate and 6-phosphogluconate in vitro, 
replace phosphate in the sodium pump, diminish formation of adenosine triphosphate 
(ATP) by replacing phosphate and deplete ATP in cellular systems (ATSDR, 2013).  
Arsenic (III) has the ability to inhibit multiple important enzymes by binding to the 
sulfhydryl group (X. Wu et al., 2016). This alone has many downstream implications, as 
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enzymes affected include but are not limited to kinases, phosphatases and caspases 
(Miller, Schipper, Lee, Singer, & Waxman, 2002).  
Arsenic (III) exposure also causes production of different forms of oxygen species 
including H2O2 and OH radicals (X. Wu et al., 2016). The production of these reactive 
oxygen species can cause inhibition of a number of cellular processes including DNA 
repair, signal transduction and genotoxicity (X. Wu et al., 2016). The disruption of these 
cellular processes is thought to be one of the main mechanisms behind the carcinogenesis 
of arsenic exposure (X. Wu et al., 2016). Arsenic (III) can also cause DNA damage 
because of its ability to replace phosphate, causing errors in DNA repair (Mandal & 
Suzuki, 2002).  
1.6 Type 2 Diabetes 
Diabetes is a worldwide problem affecting 415 million people as of 2015, with the 
number expected to increase to 642 million by the year 2040 (Federation, 2015). Type 1 
diabetes is characterized by a deficiency of the body to produce insulin, caused by an 
autoimmune disorder that causes pancreatic beta cell destruction (Federation, 2015; 
World Health Organization, 2016). Onset of the disease appears typically in childhood 
and is managed by lifelong insulin administration (Federation, 2015). Type 2 diabetes is 
the most common form, and is characterized by insulin resistance leading to high blood 
glucose (Federation, 2015). Perhaps the most challenging aspect of type 2 diabetes is that 
the disease can go undiagnosed for many years, with approximately 193 million people 
being affected and unaware (Federation, 2015). A number of different factors have been 
attributed to the development of type 2 diabetes, many of them being lifestyle 
management including poor nutrition, obesity, along with genetics and aging (Federation, 
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2015; World Health Organization, 2016). However, we are now noticing a greater 
increase in the number of type 2 diabetes cases than can’t be attributed to these factors 
alone, making room for the possibility of environmental effects (Jeon, Ha, & Kim, 2015). 
A number of studies have examined the effects of environmental contaminants on the 
progression of type 2 diabetes, including effects of persistent organic pollutants, 
bisphenol A and metals (Jeon et al., 2015). There is growing evidence that areas exposed 
to high levels of arsenic also show increased incidence of type 2 diabetes, which will be 
reviewed in the next section. 
1.7 Review of Arsenic and Type 2 Diabetes Epidemiological Studies 
A number of epidemiological studies have examined the possible link between 
iAs exposure and type 2 diabetes, specifically iAs contamination of drinking water. In 
some areas of Bangladesh and Taiwan, people are exposed to greater than 1000 µg/L, and 
these areas not only have a high correlation between arsenic exposure and black foot 
disease but also type 2 diabetes (Abernathy et al., 1999; Kuo, Moon, Thayer, & Navas-
Acien, 2013; Navas-Acien et al., 2006; W. Wang, Xie, Lin, & Zhang, 2014). As the 
levels of arsenic drop to low or moderate exposure, the correlation is not as clear, as is 
evident in Table 1.1. This can be because there is no clear mechanism discovered yet 
between arsenic exposure and type 2 diabetes, but also a number of studies have very 
different variables and exposure levels which makes drawing conclusions across the 
board impossible. In my review of the epidemiological studies available from 1998-2016, 
represented in Table 1.1, I excluded any studies that did not include original data, were 
not related to arsenic exposure in drinking water, and lacked outcomes related to diabetes 
or glucose metabolism. 
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The range of exposure between all of the epidemiological studies is vast, 
including regulated drinking water (0-10 µg/L) in the United States to the tube well 
exposure in Bangladesh and Taiwan as high as 1400µg/L. Some studies failed to report 
arsenic exposure, only reporting total urinary arsenic concentration as an indicator of 
exposure (N. H. Kim et al., 2013; Y. Kim & Lee, 2011a; Navas-Acien, 2008; Ruiz-
Navarro, Navarro-Alarcon, Lopez Gonzalez-de la Serrana, Perez-Valero, & Lopez-
Martinez, 1998; Steinmaus et al., 2009; S. L. Wang et al., 2007). While informative, 
these studies lack the appropriate information to determine how their outcomes were 
directly related to levels of arsenic exposure.   
Urinary arsenic was the primary biomarker used for arsenic exposure in the 
epidemiological studies. Compared to blood arsenic, which has a half-life of 1-4 hours, 
urinary arsenic has a half-life of 4 days (NRC, 2001). Other possible biomarkers of 
arsenic exposure include hair and nails as arsenic has a high affinity for keratin, and can 
represent months to a year of exposure, respectively (NRC, 2001). It is difficult to 
speciate arsenic from hair and nails and arsenic contamination may lie on the surface of 
these biomarkers and must be removed before analysis is performed to avoid falsely 
elevated detections (ATSDR, 2013; Mandal, Ogra, & Suzuki, 2003; Maull et al., 2012). 
Mandal et al. did show that through the use of inductively coupled plasma mass 
spectrometry (ICP-MS) it is possible to determine arsenic metabolites in these tissues, 
including iAs(III), iAs(V), DMA(III) and DMA(V). However, urinary arsenic has been 
the preferred marker for the majority of studies. 
To give an accurate representation of total urinary arsenic, dilution of urine is 
typically accounted for through the concentration of creatinine in urine. This can be 
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calculated two ways – either by measuring µg urinary arsenic per gram of urinary 
creatinine or by µg of urinary arsenic per liter of urine and measuring urinary creatinine 
as a separate variable (Maull et al., 2012). The second method is the preferred method 
because of the wide variety of individual variation in creatinine levels, however many 
studies use both of these methods (Maull et al., 2012). Another issue in the use of 
creatinine to determine urine dilution is that in diabetics, creatinine tends to be lower 
because of increased glomerular filtration and increased water intake that leads to 
increased urine dilution (Maull et al., 2012).  
Studies also differ in the method used to diagnose diabetes. The options used 
include self-report through the use of diabetic medication, physician diagnosis, fasting 
blood glucose greater than 126 mg/dL or death certificate. Most studies use fasting blood 
glucose of >127 mg/dL, but fasting times varied from 8-16 hours, with some studies 
requiring dietary restrictions leading up to the exam (i.e. no seafood, as seafood is the 
main source of organic arsenic exposure). 
A number of studies also differ in the variables considered when determining total 
urinary arsenic and diabetes. These variables include age, sex, ethnicity, body mass 
index, education, smoking, alcohol consumption and seafood consumption. These 
differences in population are very clear when comparing Meliker et al. and Lewis et al 
(2007). These studies appear to be relatively similar, both populations living in the 
United States, relying on death certificates to determine whether arsenic played a role in 
increased type 2 diabetes mortality, and both populations were exposed to below an 
average of 200 µg/L arsenic. However, the cohorts in each of these studies were very 
different, with over 2000 individuals included in the Lewis study who were all Mormon 
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whereas in the Meliker study, the cohort was significantly larger with over 80,000 
individuals living in a more urban setting. These differences alone could contribute to the 
differences in results; Lewis reported few incidences of type 2 diabetes-related deaths and 
Meliker reported higher mortality rates associated with type 2 diabetes.  
Two studies from the United States that used similar populations to evaluate 
different end points were Gribble et al. and Kuo et al. (2012, 2015). Each of these studies 
was based on populations from tribal areas of Arizona, Oklahoma, North and South 
Dakota as a part of the Strong Heart Study. These locations have similar populations that 
have low migration to other areas, which would keep the record of arsenic exposure 
consistent. They also all fall below 61 µg/L for the range of arsenic exposure. Both 
studies evaluated total urinary arsenic in relation to type 2 diabetes risk. Gribble found 
that there was no association between urinary arsenic and diabetes risk in patients without 
diabetes or with controlled diabetes. However, there was an association present in those 
who participated in the study with uncontrolled diabetes, which was defined as 
Hemoglobin A1c (Hb1Ac) ≥ 8%. Evaluating another endpoint, Kuo et al. determined that 
there was a difference in type 2 diabetes risk depending on the breakdown of arsenic 
metabolites in the urine. A higher percentage of MMA was associated with a decreased 
risk of type 2 diabetes. 
Both Navas-Acien et al. and Steinmaus et al. used data from the 2003-2004 
National Health and Nutrition Examination Survey (NHANES) study, so the populations 
were exactly the same (2008, 2009). However, each study accounted for inorganic 
arsenic in total urinary arsenic differently, which was heavily evaluated by Longnecker 
(2009). Steinmaus found no significant association in the same group of participants 
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when urinary metabolites that could come from seafood are excluded. Navas-Acien found 
a positive correlation between urinary arsenic and type 2 diabetes, and instead of simply 
subtracting organic urinary metabolites also noted that while DMA primarily comes from 
iAs exposure, seafood can also contribute to DMA levels.  
The remaining studies from the United States had relatively low numbers of 
participants and were mixed in their results. Both Kim et al and James et al found mild 
associations for the risk of type 2 diabetes with low arsenic exposure (2013, 2013). 
Zierold et al. however found no association (2004). Both Kim et al. and James et al., 
required medical examination for participants, meaning individuals were diagnosed 
diabetic either by self-diagnosis with a medical follow up or by glucose tolerance test, 
where Zierold was only with self-diagnosed, lacking medical follow-up. These 
differences in methods could lead to inconsistencies in diabetes reports at the conclusion 
of studies. 
Another issue with study design is that a number of the studies take place within 
the same area, meaning that population overlap can be a problem. For example, the 
studies that originated from Taiwan (Tsai et al., 1999; C.-H. Tseng et al., 2000; S. L. 
Wang et al., 2003, 2007) all came from populations in the same area, which may skew 
the only positive correlations between arsenic and diabetes found in these studies. The 
same could be said for the studies that came out of Bangladesh (Y. Chen et al., 2010; 
Islam et al., 2012; Nabi et al., 2005; M. Rahman et al., 1998). However, Chen et al. found 
no evidence that type 2 diabetes was associated with arsenice exposure in the Bangladesh 
population (2010). This study had large participation (n=11,319) and a wide range of 
arsenic exposures, but the number of diabetes cases present was approximately 2% of the 
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group. It is impossible to account for all of these variables within each study, however 
this is a clear example of how streamlined variables need to be accounted for in 
epidemiological studies.  
1.8 Review of Arsenic and Type 2 Diabetes in Vivo Studies 
Attempting to link the effects of arsenic and type 2 diabetes in vivo has had many of 
the same complications that are present in epidemiological studies. These include, but are 
not limited to: animal model used, differences in arsenic species, duration of exposure, 
route of exposure and sampling methods. A number of animal models have been used to 
investigate the potential role of arsenic on type 2 diabetes development, including mice, 
rats, hamsters and guinea pigs. However, each of these animals metabolize arsenic 
slightly differently from each other as well as humans. When evaluating urinary 
metabolite breakdown, mice are the most similar to humans and one of the better options 
for arsenic studies, with hamsters following up as a second choice (Mitchell, Ayala-fie, & 
Carter, 2000). Rats are not suitable models as these models sequester arsenic in red blood 
cells, which is very different from human metabolism. As such, only experimental studies 
evaluating arsenic exposure and diabetic endpoints in mice will be reviewed.  
In Table 1.2, it is apparent that a wide range of arsenic concentrations have been used 
in mice, from 50 µg/L to 5x104 µg/L, which is orders of magnitude higher than human 
exposures. However, higher concentrations of arsenic can be justified in mouse studies 
because mice are known to have an overall faster metabolisms compare to humans.  
The most common strain of mice used was C57BL/6, which could be because these 
mice, when fed a high fat diet, are excellent models for obesity and diabetes. Also used 
were ICR mice, which is an outbred strain, B6C3F1 mice that are a hybrid between 
 16 
C57BL/6 females and C3H males, and Swiss albino mice which are frequently used in 
toxicology studies. One study also used diabetic C57BKS/Lepdb (db/db) mice and the 
heterozygote (db/+) as a control (Liu et al., 2014). While the study by Huang et al. 
included a non-diabetic variable (estrogen), it was essential to include this in the analysis, 
as it is the only study that used female mice (2015). This is because it has been 
demonstrated that there are differences in metal toxicity between males and females in 
not only arsenic, but other metals as well (Marie Vahter, Åkesson, Lidén, Ceccatelli, & 
Berglund, 2007) 
Each study had a difference range and duration of arsenic exposure, ranging from a 
single acute exposure to 20 weeks of chronic exposure. The most common route of 
exposure was drinking water, although Mitchell et al. used intraperitoneal injection 
(2000). A major problem with using arsenic in drinking water is that iAs(III) can oxidize, 
so water must to be changed frequently. Another problem with arsenic in drinking water 
is that depending on the number of mice in a cage, there was no way to definitively 
determine how much arsenic each individual mouse drank. Finally, in some studies the 
mice with arsenic in the drinking water actually consumed less water than the controls (D 
S Paul, Devesa, & Hernandez-Zavala, 2008; David S. Paul, Hernandez-Zavala, et al., 
2007; David S. Paul, Walton, Saunders, & Styblo, 2011) which caused a reduction in the 
overall arsenic exposure. Paul et al. concluded that because of the reduced arsenic 
consumption in their low fat diet (LFD) treated mice, concentrations well above 
5x104µg/L would have to be used to produce enough arsenic accumulation in tissues to 
produce a change in glucose tolerance toward a diabetic phenotype (2011). 
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Methods to evaluate glucose tolerance also varied from study to study (Table 1.2) 
with fasting times ranging from 5 to 14 hours. Glucose bolus was either 1 g/kg or 2 g/kg 
body weight with either oral glucose tolerance test (OGTT) or intraperitoneal glucose 
tolerance test (IPGTT) was used to determine glucose tolerance, and glucose 
measurements were typically taken at 0, 15, 30, 60, 90, and 120-minutes post glucose 
bolus. The different conditions behind the oral glucose tolerance test have been tested to 
determine ideal conditions (Andrikopoulos, Blair, Deluca, Fam, & Proietto, 2008). 
Fasting for long periods of time (i.e. overnight) resulted in high fat and chow fed mice 
having no differences in basal glucose and insulin levels, but 6 hours of fasting resulted 
in a clear difference in glucose tolerance comparing high fat and chow fed animals 
(Andrikopoulos et al., 2008). When comparing IPGTT and OGTT, IPGTT has a 10-20% 
rate of error if the needle punctures the intestines or stomach, as well as differences in 
glucose profiles. Plasma glucose levels are lower in the OGTT and IPGTT plasma insulin 
increases at a slower rate (Andrikopoulos et al., 2008). Finally, they also examined the 
amount of glucose to give mice, and when comparing 0.5 g/kg, 1 g/kg and 2 g/kg 
glucose, only the 2 g/kg dose made a clear difference between chow and high fat diet. 
With all of these variables between in vivo studies, only Mitchell et al. failed to report 
arsenic having an impact on glucose tolerance (2000). A number of studies did report 
issues with water consumption in the arsenic treated groups (D S Paul et al., 2008; David 
S. Paul, Hernandez-Zavala, et al., 2007; David S. Paul et al., 2011), which resulted in 
lower overall exposures to arsenic. Finally, since the majority of studies use only male 
mice (Huang et al. is one exception since they used female mice), this did not allow for 
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an evaluation of whether there are sex-based differences in arsenic exposure, metabolism 
and glucose tolerance. 
1.9 Review of Arsenic and Type 2 Diabetes in Vitro Studies  
A number of in vitro studies have been conducted to provide a possible 
mechanism behind arsenic and type 2 diabetes in mouse adipocytes, focusing primarily 
on insulin-stimulated glucose uptake (ISGU). One problem caused by arsenic that has 
been evaluated by a number of studies is the inhibition of differentiation into adipocytes 
(Trouba, Wauson, & Vorce, 2000; Z. X. Wang et al., 2005; Wauson, Langan, & Vorce, 
2002). This can be caused by exposure to arsenic reducing adipocyte protein 2 (aP2), 
peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT/enhancer-
binding protein alpha (C/EBPα), which are all important adipocyte markers (Wauson et 
al., 2002). Also in 3T3-L1 adipocytes, 3uM arsenic trioxide was shown to inhibit PPARγ 
and retinoid x receptor alpha (RXRα), as well as inhibiting interactions between 
serine/threonine kinase Akt (or protein kinase B -PKB) and PPARγ, halting 
differentiation in a reversible manner (Z. X. Wang et al., 2005). Hou et al., 2013, also 
showed a reduction in adipogenesis caused by inducing the endoplasmic reticulum (ER) 
stress response and upregulated CCAAT/enhancer-binding protein homologous protein 
10 (CHOP10), which will inhibit CCAAT/enhancer-binding protein beta (C/EBPβ) and 
suppress adipogenesis.  
Another problem caused by arsenic is the inability of glucose transporter type 4 
(GLUT4) to translocate to the cell membrane, which does not allow for glucose uptake 
by the cell (David S. Paul, Harmon, Devesa, Thomas, & Styblo, 2007; Walton et al., 
2004; Xue et al., 2011). A number of possible arsenic targets have been identified, 
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including PKB/Akt, which can be reduced by arsenic exposure (Walton et al., 2004) and 
downregulation of GLUT4 expression (Xue et al., 2011).  
All of these problems can also be attributed to the induction of oxidative stress in 
the adipocytes by arsenic. Salazard et al. demonstrated an increase in Heme oxygenase 1 
in adipocytes treated with arsenic, which is involved in oxidative stress along with an 
increase in hypoxia-inducible factor 1 alpha (HIF1α) expression (2004). NAD-dependent 
deacetylase sirtuin-3 (Sirt3) expression and target proteins forkhead box  P3a (FOXO3a), 
manganese superoxide dismutase (MnSOD), and peroxisome proliferator-activated 
receptor gamma, coactivator 1 alpha (PGC-1α) were also reduced in long term, low level 
arsenic exposure (Divya et al., 2015). These studies support the idea that arsenic can 
induce oxidative stress, which can possibly be a cause of insulin resistance.  
 While these studies are very promising at providing potential mechanisms 
between arsenic and type 2 diabetes, unfortunately none of them have been supported in 
vivo or in a human system.  
1.10 Arsenic and Inflammation 
Finally, we will examine the effects of arsenic on the immune system. Depending 
on the concentration and species of arsenic, very different impacts occur on the immune 
system. When taking this into consideration in the context of diabetes, a disorder that is 
normally associated with higher body mass index (BMI), another layer of inflammation is 
added. The baseline inflammatory profiles between lean and obese individuals are very 
different, so it would be expected that exposure to arsenic would impact these scenarios 
very differently (Ferrante, 2007). The effects of arsenic on inflammation in humans and 
mice have been extensively reviewed by (Dangleben, Skibola, & Smith, 2013; Mandal & 
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Suzuki, 2002; Tobergte & Curtis, 2013). According to these sources, arsenic can not only 
affect gene expression, but cell population, apoptosis, and ROS production in a number 
of different immunological cell types. Because of the role of macrophages in obesity and 
the differences in macrophages present in lean vs. obese individuals, we wanted to 
explore the effects of arsenic on these immune cells in greater detail. 
 In humans, the majority of the studies have examined the effects of arsenic on 
circulating peripheral blood mononuclear cells (PBMCs), not directly on macrophages. In 
these studies, a number of different results have been seen depending on the 
concentration of arsenic in question. In Bangladesh, a study examining 16 individuals, 5 
control and 11 with skin lesions, reported downregulation of important immunological 
genes, such as tumor necrosis factor alpha (TNF-α), expressed by PBMCs in circulation 
(Argos et al., 2006). Another study in Mexico with 10 individuals, 5 control and 5 having 
urinary arsenic concentrations ranging from 117.23-435.12 mg/g creatinine, 
demonstrated that arsenic exposure correlates to suppression of a number of 
inflammatory genes (Salgado-Bustamante et al., 2010). Both of these studies are 
contradicted by a third study from Taiwan, with 24 individuals exposed to a range of 
different concentrations of arsenic up to 46.5 µg/L  (M.-M. Wu, Chiou, Ho, Chen, & Lee, 
2008). This study documented an increase in gene expression in interleukin 1-beta (IL-
1β), interleukin 6 (IL-6), chemokine ligand 2 (CCL2) and cluster of differentiation 14 
(CD14), all of which would indicate an increase in a pro-inflammatory immune 
environment. 
 When comparing the effects of arsenic on macrophages in mice and humans the 
results are very similar. Studies reported reduced macrophage adhesiveness, reduced 
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cytokine response, and reduced nitric oxide production (Banerjee et al., 2009; 
Bourdonnay et al., 2009; Sengupta & Bishayi, 2002; Srivastava et al., 2013). However, in 
one study with PBMC-derived macrophages exposed to arsenic, as little as 1 µM As2O3 
caused an exacerbated response to LPS as measured by TNF-α and interleukin 8 (IL-8) 
mRNA production (Lemarie, Morzadec, Bourdonnay, Fardel, & Vernhet, 2006). Studies 
in mice were performed either in peritoneal macrophages that were subsequently exposed 
to arsenic, mice exposed to arsenic peritoneally then isolating macrophages from spleen, 
or from strict cell culture using RAW264.7 cells (Sakurai et al., 2004; Sengupta & 
Bishayi, 2002; Srivastava et al., 2013). In studies using sub-toxic levels of arsenic, 
diminished macrophages functions as well as decreases in cytokines were present 
including TNF-α, IL-1β, IL-6, transforming growth factor beta (TGF-β) and IL-10 
(Sengupta & Bishayi, 2002; Srivastava et al., 2013). In another study, cytotoxic doses of 
arsenic were used and an increase in TNF-α was reported (Sakurai, Kaise, & Matsubara, 
1998). 
 Overall, a number of the studies investigating the effect of arsenic on 
macrophages demonstrate the ability of the toxicant to reduce macrophage function, 
diminish cytokine production and reduce nitric oxide production. The greatest differences 
in study design occur in the concentration of arsenic used (cytotoxic vs non-cytoxic) or in 
the method of arsenic exposure (PBMCs exposed to arsenic in vitro or PBMCs exposed 
to arsenic in vivo then analyzed). As demonstrated in the epidemiological and in vivo 
studies examining effects on arsenic, any small change between conditions can produce 
very different results. 
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1.11 Our Study in Arsenic and Type 2 Diabetes 
In our study, we chose to use C57BL/6 mice along with the diabetic 
C57BKS/Lepdb db/db and db/+ mice, however because of breeding issues we were left 
with a large number of db/+ mice. These are considered the control in a number of 
diabetes studies, so we wanted to see how these mice would compare to the background 
C57BL/6 mice. We also chose to use both males and females in this study to determine 
whether sex differences impacted the effects of arsenic exposure.  
We chose to use AsCl3 for safety reasons, as it was the only option in solution that 
was available. When added to water, it dissociates into iAs(III) and HCL at negligible 
amounts. We used 0, 50 or 500 µg/kg concentrations and chose to deliver this by oral 
gavage instead of in drinking water because we could guarantee each individual mouse 
would receive the desired amount of arsenic. These concentrations also represent low 
level exposure, as 50 µg/kg in a 20g mouse is a final exposure of 1 µg every other day – 
which according to Table 1.3 is lower than most in Vivo studies have examined. The 
second concentration, 500 µg/kg, is a final exposure of 10 µg every other day in a 20g 
mouse, which while high is still not out of the range of previously studied concentrations 
of arsenic in mice (Table 1. 3). Finally, for the in vitro study, we chose to use Raw 264.7 
macrophages to determine the effect of arsenic on inflammation. Macrophages are an 
important component of obesity and a number of studies have examined the effects of 
PBMCs, but have not looked at the effect directly on macrophages. 
Our goal for this study was to evaluate in a diabetic model the effects of low dose 
arsenic exposure on the progression of type 2 diabetes development. We could claim that 
we were measuring progression of the disease by the time point analysis of the dual 
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energy X-ray absorptiometry (DEXA) scan and OGTT, which would have told us if 
glucose tolerance was worsening over the period of arsenic treatment or if obesity was 
increasing. We wanted to start the mice at a young enough age that obesity and glucose 
dysregulation had not yet begun to be apparent. Our hypothesis based on the background 
information provided was that arsenic exposure would increase inflammation, leading to 
a diabetic phenotype in non-susceptible individuals.
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Table 1.1 Summary of Studies Examining Arsenic Exposure in Humans. 
Reference Location, number of 
participants 
Range of Exposure Endpoint Conclusion 
(Y. Chen et al., 2010) 
Cross-section 
Bangladesh 
 n = 11,319 
Range = 0.1-864 µg/L Total urinary arsenic and 
HB1AC levels 
No association between arsenic 
exposure and T2D 
(Coronado-Gonzalez, Maria 
Del Razo, Garcia-Vargas, 
Sanmiguel-Salazar, & 
Escobedo-de la Pena, 2007) 
Case-Control 
Mexico 
n = 400 
cases = 200 
Range 20-400 µg/L Total urinary arsenic No association at low levels of 
urinary arsenic 
High levels (>104 µg/g) have 
2.65x higher probability of T2D 
development 
(Del Razo et al., 2011) 
Cross-section 
Mexico 
n = 258 
Mean = 42.9 µg/L 
Range = 3.1-215.2 
µg/L 
Urinary arsenic 
metabolites, fasting 
blood glucose and 2-
hour blood glucose 
Found significant association 
with arsenic concentration in 
drinking water and fasting 
blood glucose and 2-hour blood 
glucose 
(Feseke, Ayotte, Bouchard, & 
Levallois, 2015) 
Cross-section 
Canada 
 n = 3151 
 
Municipal sources - 
<10 µg/L 
Private wells - 
undisclosed 
Total urinary arsenic Higher urinary arsenic levels 
present in those with T2D and 
prediabetes 
(Gribble et al., 2012) 
Cross-section 
US – Arizona, Oklahoma, 
North and South Dakota 
n total = 3925 
  Nondiabetic n = 1,986 
Diabetic n = 1,939 
Range = 1-61 µg/L Total urinary arsenic 
HBA1C 
No association between urinary 
arsenic and HBA1C or insulin 
resistance in people w/o 
diabetes 
Association restricted to 
patients with uncontrolled 
diabetes 
(Islam et al., 2012) 
Cross-section 
Bangladesh 
n = 1004 
Mean = 159 µg/L 
Range = 10-1401 µg/L 
Risk of T2D 
development 
Increased risk for T2D 
development in >50 µg/L, 
greatest risk at >250 µg/L for 
greater than 10 years 
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(James et al., 2013) 
Cases-Control 
United States – San Luis 
Valley 
Nondiabetic n =488 
Diabetic n = 60 
Mean 39 µg/L 
Range – undetectable - 
752 µg/L 
T2D Risks Mild association for T2D risk at 
levels <100 µg/L 
 
(Jovanovic et al., 2013) 
Cross-section 
Serbia 
 Unexposed n = 1,324,489 
Exposed n = 195,190 
No exposure  
vs 
56.1 µg/L 
Number of diabetic cases 
present 
Higher number of diabetes 
cases in exposed region 
(Y. Kim & Lee, 2011b) 
Cross-section 
Korea 
n = 1677 
No range given Total urinary arsenic Higher urinary arsenic levels 
present in those with T2D 
(N. H. Kim et al., 2013) 
Case-control 
United States 
n = 300 
No range given Risk of T2D 
development 
Slight association between 
arsenic exposure and T2D risk 
(Kuo et al., 2015) 
Case-Control 
United States – Arizona, 
Oklahoma, North and South 
Dakota 
n total = 3925 
  Nondiabetic n = 1,986 
Diabetic n = 1,939 
Range = 1-61 µg/L Urinary arsenic 
metabolites 
Higher MMA% in urine 
associated with decreased T2D 
risk  
(Lewis et al., 1999) 
Retrospective 
United States – Utah 
n females = 961 
n males = 1,242 
<200 µg/L Mortality analysis Few incidence of death 
attributed to T2D 
(Li et al., 2013) 
Cross-Section 
China 
n = 669 
Range = 0-760 µg/L Risk of T2D 
development 
No significant association 
between arsenic and T2D risk 
(Meliker et al., 2007) 
Retrospective 
United States – Michigan 
n females = 41,282  
n males = 38,722 
Average 11.0 µg/L 
 
Mortality analysis Higher mortality rates observed 
for T2D 
(Nabi et al., 2005) 
Case-control 
Bangladesh 
n = 235 
Mean = 11.3 vs 218 
µg/L 
Range = 3 - 875 µg/L 
Risk of T2D 
development 
Diabetes prevalence in exposed 
individuals 2.8x higher than 
unexposed 
(Navas-Acien, 2008) 
Case-Control 
United States 
n = 788 
No range given Total urinary arsenic Total urinary arsenic levels are 
associated with increased T2D 
(M. Rahman et al., 1998) 
Cross-section 
Bangladesh 
Unexposed n = 854 
Keratosis n = 251 
I - <500 µg/L 
II – 500-1000 µg/L 
III – 1000 µg/L < 
Number of diabetic cases 
present 
Increase in T2D cases in 
patients with keratosis 
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(Ruiz-Navarro et al., 1998) 
Case-control 
Spain 
n = 89 
 
No range given Risk of T2D 
development 
No correlation to urinary 
arsenic and T2D incidence 
(Steinmaus et al., 2009) 
Cross-section 
United States 
Nondiabetic n = 697 
Diabetic n = 98 
No range given Total urinary arsenic No association between T2D 
and urinary arsenic 
(Tsai et al., 1999) 
Retrospective 
Taiwan 
n = 19,536 
 
Mean = 790 µg/L 
Range = 250-1140 
µg/L 
Mortality analysis Found correlation between 
arsenic exposure and T2D 
related mortality 
(C. H. Tseng et al., 2000) 
Cohort 
Taiwan 
n = 446 
Range = 700-930 µg/L Risk of T2D 
development 
Correlation between long term 
arsenic exposure and T2D 
(J. P. Wang et al., 2009) 
Cross-section 
China 
n = 235 
Range = 16-272 µg/L Risk of T2D Blood glucose is lower and 
urinary arsenic higher in 
arsenic exposed individuals 
(S. L. Wang et al., 2003) 
Cross-section 
Taiwan 
n = 27,543 
Range >350 µg/L Risk of T2D Increased levels of T2D in 
arseniases areas 
(S. L. Wang et al., 2007) 
Cross-section 
Taiwan 
n = 660 
No range given Risk of T2D Found correlation between 
arsenic in hair and increased 
blood glucose 
(Zierold et al., 2004) 
Case-Control 
US – Wisconsin 
n = 1885 
 
<2µg/L 
2-10 µg/L 
10 µg/L< 
Evaluate prevalence of 
chronic illness in 
population 
No significant association 
found 
MMA – monomethylarsonic acid T2D- type 2 diabetes 
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Table 1.2 Summary of in Vivo Studies Examining Arsenic and Type 2 Diabetes 
 In Vivo Study Parameters Glucose Tolerance Test 
Reference Strain 
 
Exposure Endpoint Conclusion Glucose 
Test 
Fasting Time 
& Glucose 
Bolus 
Measurement 
Times (min) 
(Huang et al., 
2015) 
ICR 
7-13 week old 
females 
Arsenic trioxide 
(0, 50, 500 µg/L) 
in drinking water 
+ ovariectomized 
or sham 
Glucose 
tolerance 
and 
estrogen 
Arsenic 
increased blood 
glucose in 
sham mice, and 
caused an even 
greater increase 
in 
ovariectomized 
mice 
OGTT Overnight 
1g/kg 
0, 15, 45, 75, 
105  
(Liu et al., 
2014) 
C57BKS/Lepdr 
(db/db and db/+) 
7-23 week old 
males 
Sodium Arsenite 
(0, 3000 µg/L) in 
drinking water 
Glucose 
tolerance 
Decreased 
glucose 
tolerance in 
db/db mice 
 
OGTT 12 hours 
2g/kg 
 
0, 15, 30, 60, 
90, 120 
(Mitchell, 
Ayala-Fierro, 
et al., 2000) 
B6C3F1 
Male adult 1x 
exposure I.P. 
Sodium Arsenite 
(0, 100, 1000 
µg/L) 
Sodium Arsenate 
(0, 100, 1000 
µg/L) 
Blood 
arsenic 
Blood 
glucose 
Blood arsenic 
not a sign of 
toxicity 
No changes in 
blood glucose 
Blood 
Glucose 
x x 
(David S. Paul, 
Hernandez-
Zavala, et al., 
2007) 
C57BL/6 
4-12 week old 
males 
iAsIII (0, 2.5x104, 
5x104 µg/L) in 
drinking water 
Glucose 
tolerance 
Decreased 
glucose 
tolerance in 
IPGTT 5 hours 
2g/kg 
0, 15, 30, 60, 
90, 120 
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50ppm 
treatment group 
(D S Paul et 
al., 2008) 
C57BL/6 
4-12 week old 
males 
iAsIII (0, 1x103, 
1x104, 2.5x104, 
5x104 µg/L) or 
MAsIII(0, 100, 
1x103, 2.5x103, 
5x103 µg/L) in 
drinking water 
Glucose 
tolerance 
iAsIII impaired 
glucose 
tolerance at 
5x104 µg/L 
IPGTT 5 hours 
2g/kg 
0, 15, 30, 60, 
90, 120 
(David S. Paul, 
Walton, 
Saunders, & 
Styblo, 2011) 
C57BL/6 
4-24 week old 
males 
iAsIII (0, 2.5x104, 
5x104 µg/L) in 
drinking water 
+ high or low fat 
diet 
Glucose 
tolerance 
Higher blood 
glucose in HFD 
at 5x104 µg/L 
compared to 
LFD   
OGTT Overnight 
2g/kg 
0, 15, 30, 60, 
90, 120 
(S. Rahman, 
Hossain, & 
Rahmatullah, 
2016) 
Swiss Albino 
Mice 
Male adult 1x 
exposure 
Sodium Arsenite 
(0, 100, 200, 400 
µg/20g body 
weight) orally 
Blood 
glucose 
 
Blood glucose 
elevated at all 
levels of 
arsenic 
exposure 
 
OGTT Overnight 
2g/kg 
120 
(Rodríguez, 
Limón-
Pacheco, Del 
Razo, & 
Giordano, 
2016) 
C57BL/6 
Adult male 1 or 
2-month 
exposure 
Sodium Arsenite 
(0, 5x104µg/L) in 
drinking water 
Blood 
glucose 
1 month did not 
alter serum 
glucose levels 
2 months 
decreased 
glucose 
tolerance 
IPGTT 12 hour 
2g/kg 
0, 30, 90, 150 
OGTT- oral glucose tolerance test, IPGTT, intraperitoneal glucose tolerance test
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Figure 1.1. Urinary inorganic arsenic metabolites. Common metabolites found in 
urine that can be attributed to inorganic arsenic exposure are inorganic arsenic (iAs) (III) 
and (V), monomethylarsonous acid (MMA) (III) and (V) and dimethylarsonous acid 
(DMA) (III) and (V). Percentages are estimates of the concentrtion typically found in 
human urine samples. 
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Figure 1.2. Summary of arsenic exposure by country. Arsenic exposure varies from country to country, and presented are the 
ranges of exposures that have been examined in epidemiological studies.  
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Figure 1.3. Range of in Vivo exposure compared to human exposure. In Vivo studies have attempted to provide a 
link between arsenic exposure and type 2 diabetes, however these animal exposures tend to be much higher than to 
human exposures. 
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Chapter 2 – Arsenic and Type 2 Diabetes in C57BL/6 Mice 
2.1 Introduction  
Arsenic is an element found in the earth’s crust that can be found in organic and 
inorganic forms, with the inorganic form being a known toxin. Typical total arsenic 
exposure is about 50 µg/day from a variety of sources, with about 3.5 µg/day coming 
from the inorganic form and the rest coming for non-toxic organic sources such as 
seafood (ATSDR, 2013). The main sources of inorganic arsenic exposure are from food 
and water.  
In the United States, the amount of arsenic in public drinking water is very highly 
regulated, having been reduced from 50 µg/L to 10 µg/L by the EPA in 2001 because it is 
a known carcinogen (ATSDR, 2013). In other countries however, the levels of drinking 
water are not regulated and individuals are exposed to up to ten times the amount of 
arsenic as in the United States. These include Bangladesh and Taiwan, where the well 
water can be on the order of 1000 µg/L, leading to increased risks for health issues 
including hyper-pigmentation, cardiovascular disease and type 2 diabetes, which have 
been heavily reviewed (Becker & Axelrad, 2014; Huang et al., 2011; Navas-Acien et al., 
2006; Thayer, Heindel, Bucher, & Gallo, 2012; W. Wang et al., 2014). Other at risk areas 
include rural populations in the United States that rely on well water and do not regularly 
check for contaminants, as these sources of drinking water are not regulated. The 
concentration of arsenic in these wells can also reach critical levels of almost 800 µg/L 
(James et al., 2013).
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Type 2 diabetes is a metabolic disease that results in high blood sugar and insulin 
resistance (Mathers & Loncar, 2006). This disease is typically considered a lifestyle 
disorder resulting from inactivity, poor diet and high body mass index (BMI), but more 
recently aging and genetic components are recognized to play a role in disease 
development (Federation, 2015). In 2015, 415 million people were affected by type 2 
diabetes with the number expected to increase to 642 million by the year 2040 
(Federation, 2015). This increase in population is much greater than can be attributed to 
lifestyle, age and genetics alone, which has led to research examining environmental 
contaminants in the development of the disease, including but not limited to cadmium, 
mercury and arsenic (Y. W. Chen et al., 2009). 
While at higher levels positive correlations between arsenic exposure and type 2 
diabetes have been demonstrated in the epidemiological data, at mid and lower level 
exposure (<500µg/L) the results are inconclusive. Because of inconsistent methodologies, 
comparing and contrasting data between studies at these levels is nearly impossible. The 
same trend can be observed in animal studies, where at higher exposures glucose 
intolerance can be induced by arsenic either acutely or chronically (Kuo et al., 2013). 
While mice metabolize arsenic more rapidly than humans, the majority of these studies 
use doses well beyond what would be considered relevant exposures for human studies.  
In our study, we proposed to examine the diabetic effects of arsenic exposure on a non-
susceptible mouse strain at a concentration of arsenic that is closer to low-level exposure 
in humans. The goal will be to determine if the lower level of arsenic we are exposed to 
in the United States, which is highly regulated, is still enough to be concerned about 
diabetes susceptibility. We will evaluate body composition, glucose tolerance and 
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adipokine expression to elucidate a possible mechanism behind arsenic exposure leading 
to the development of diabetes. We hypothesized that arsenic exposure would increase 
obesity and decrease glucose regulation allowing for progression toward a diabetic 
phenotype. 
2.2 Methods and Materials 
2.2.1 Animals 
Male and female B6.BKS(D)Leprdb/J heterozygote mice were bred and housed at 
the University of South Carolina Animal Resource Facility. Offspring of the heterozygote 
x heterozygote cross were genotyped by RT-PCR followed by a restriction digest for the 
Leptin gene at weaning (3 weeks of age).  The primer sequences were forward: 5’-
AGAACGGACACTCTTTGAAGTCTC-3’; and reverse: 5’-
CATTCAAACCATAGTTTAGGTTTGTGT-3’. PCR products were digested using RsaI 
enzyme, which cleaved sequences into one 135 base pair band or 27, 108, and 135 base 
pair bands representing wildtype or heterozygous genotypes, respectively. Once 
genotyped, animals were randomly grouped into control, 1x inorganic arsenic (AsCl3 - 
Alfa Aesar, 50 µg/kg body weight) or 10x inorganic arsenic (500 µg/kg body weight) and 
were treated every other day beginning at 4 weeks of age (Figure 2.1). These doses, 
relating to human exposure, are 0, 1 and 10 µg every other day, respectively in a 20-g 
mouse. This spectrum is broad enough to include a level of exposure lower and consistent 
with current literature (Huang et al., 2015; Liu et al., 2014; Mitchell, Ayala-Fierro, et al., 
2000; D S Paul et al., 2008; David S. Paul, Hernandez-Zavala, et al., 2007; David S. Paul 
et al., 2011; S. Rahman et al., 2016; Rodríguez et al., 2016). Mice received 100 µl/20 g 
body weight of the appropriate dilution of arsenic (or diluent water for controls) via oral 
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gavage using a flexible gavage needle. Weights were recorded every other day, and every 
4 weeks an oral glucose tolerance test (OGTT) and Dual Energy X-ray Absorptiometry 
(DEXA) scan were performed. Animals were maintained on a 12:12 hour light cycle and 
given food and water ad libitum. At 12 weeks, animals were euthanized for tissue 
collection using isoflurane overdose followed by cervical dislocation. Principles of 
laboratory animal care were followed and the Institutional Animal Care and Usage 
Committee of the University of South Carolina approved all protocols.  
2.2.2 Body composition  
Along with monitoring weight every other day, body composition was assessed 
every four weeks (weeks 4, 8 and 12 of age). Mice were lightly anesthetized with 
isoflurane and measurements were taken to determine lean mass, fat mass and body fat 
percentage for each mouse by dual-energy X-ray absorptiometry (DEXA) (Lunar 
PIXImus, Madison, WI).  
2.2.3 Glucose tolerance 
An oral glucose tolerance test (OGTT) was performed every four weeks following 
arsenic exposure starting at 4 weeks old (weeks 4, 8 and 12 of age). Mice were fasted for 
4 hours during their sleep cycle before initiating the OGTT with a fasting blood glucose 
level. Glucose was given orally (2 mg/kg body weight) and blood glucose measurements 
were taken from tail vein prick at 15, 30, 60, 90 and 120 minutes using TRUE test strips 
and glucometer. Area under the curve (AUC) for the glucose tolerance test was calculated 
using the trapezoidal rule. 
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2.2.4 Tissue collection  
Following 8 weeks of control or arsenic treatment, mice were euthanized for 
tissue collection. Reproductive fat pads were collected for histology, preserved for 24 
hours in 4% paraformaldehyde and then transferred to 70% ethanol before histology, or 
snap frozen on dry ice and stored at -80ºC for triglyceride, protein and RNA analysis. 
Spleen, liver, kidney, quadricep muscle and heart were also snap frozen and stored at -
80ºC for protein and RNA analysis. 
2.2.5 Histology  
Reproductive adipose tissue was sectioned and stained with hemotoxylin and 
eosin (H&E) to evaluate adipocyte size and diameter. Slides were evaluated using 
AxioVision LE 4.8 software and ImageJ plugin Adiposoft (ver. 1.13) to measure 
circumference and diameter for at least 2 fields of view for each section of tissue. 
Histological score was conducted by two blinded reviewers independently and averaged. 
2.2.6 Real-time PCR  
RNA was isolated from reproductive adipose tissue by Isolate RNA kit according 
to the manufacturer’s protocol (Bioline). RNA was converted to cDNA using SensiFAST 
cDNA synthesis kit according to manufacturer’s protocol (Bioline). Real-time PCR 
(qPCR) was then performed on 100 ng of cDNA using SensiFAST SYBR (Bioline) and 
10 µM of designed and validated primers according to manufacturer’s protocol. Custom 
primers (Table 2.1) were designed for each target using Primer Blast Search (NCBI) and 
purchased from Integrated DNA Technologies (IDT) for qPCR. Gene expression patterns 
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for each gene were normalized to the expression of the housekeeping gene RPLP0 and 
quantified using the ΔΔCT method. 
2.2.7 Triglycerides 
Triglycerides were measured using saponification as previously described by 
Jouihan (2012) using reagents from Sigma. Briefly, tissues were weighed and then 
digested overnight at 55°C in ethanolic KOH. Digested tissue was diluted with 50% 
ethanol, and 200 µl added to 215 µl 1M MgCl2. Samples were put on ice for 10 minutes. 
Glycerol Standard Solution (2.5 mg/ml) was used to create a standard curve, and Free 
Glycerol Reagent was used to spectrophotometrically determine triglyceride levels at 
540nm based on the 8-point standard curve generated in triplicate. 
2.2.8 Statistics 
All statistical analyses were carried out using R (version 3.3.1) or GraphPad 
Prism 7 (San Diego, CA). The n for each treatment group were as follows: male wild-
type control (n=5), male wild-type arsenic (n=4), male heterozygote control (n=11), male 
heterozygote arsenic 1x (n=8), male heterozygote arsenic 10x (n=3), female wild-type 
control (n=6), female wild-type arsenic (n=5), female heterozygote control (n=9), female 
heterozygote arsenic 1x (n=6), female heterozygote arsenic 10x (n=3), unless otherwise 
noted. Three mice were excluded from all analyses as they were outliers in more than 3 
different categories analyzed. Data are expressed as mean ± SEM. Regression analysis 
were performed to compare exposure, genotypic and sex differences. A p-value of <0.05 
was considered statistically significant.   
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2.3 Results  
2.3.1 Weight change 
To determine whether arsenic affects the development of type 2 diabetes which 
has an obesity component to the disease, we examined how exposure alters body 
composition. We weighed mice every other day during the dosing period, and found that 
when compared to the wild-type control, the slope of the male heterozygote control and 
1x treatment group were significantly steeper showing greater change in weight (Figure 
2.2a).  This means that not only were there genotypic differences in weight gain, but 
treatment based differences as well. However, the increase in arsenic exposure in the 
heterozygotes from 1x to 10x did not further affect the weight change (Figure 2.2b). 
When comparing the same effects in the females, all slopes in the change in weight were 
significantly different from the wild-type control (Figure 2.3). This means that all groups 
gained weight faster than the control, demonstrating both genotypic and treatment based 
effects on weight.  
2.3.2 Body composition analysis 
From 4-8 weeks in males, there are no differences in body composition caused by 
exposure to arsenic (Figure 2.4a). After the full dosing period (4-12 weeks), there is a 
significant difference in the control wild-type and heterozygous males (Figure 2.4b). 
While not significant, it does appear that arsenic causes a slight increase in fat mass and 
percentage in wild-type males exposed to arsenic over the entire 12-week period (Figure 
2.4b). In the heterozygote dose-response, arsenic appears to actually reduce the fat mass 
from 4-8 weeks (Figure 2.4c). This trend is no longer present after the full dosing period 
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(4-12 weeks), but the lean mass appears to be reduced in the 10x arsenic exposure group 
compared to the other two treatments and the percent fat increased (Figure 2.4d). 
 In females there are small genotypic differences present starting between 4-8 
weeks (Figure 2.5a) demonstrated by the female heterozygous controls having slightly 
greater change in lean, fat and total mass compared to the wild-type control. These 
changes are exaggerated when evaluating differences from 4-12 weeks (Figure 2.5b), as 
the change in lean, fat and total mass are significantly greater in the heterozygote controls 
compared to wild-type controls. In the heterozygote dose response, from 4-8 weeks the 
10x arsenic treatment has a significant effect on the change in lean and total mass (Figure 
2.5c); however, these changes do not persist through the entire dosing period (Figure 
2.5d). 
2.3.3 Oral glucose tolerance test 
We hypothesized that if arsenic increased the risk of developing type 2 diabetes, 
then we would see a decrease in glucose tolerance. Overall, arsenic did not appear to 
have a major impact on the OGTT in males (Figure 2.6) We chose to break down the 
glucose tolerance test into 2 measurable components – fasting blood glucose and area 
under the curve. Arsenic does not affect the fasting blood glucose in males when 
comparing wild-type to heterozygote over the 8-week dosing period (Figure 2.7). It 
appears that the male heterozygotes exposed to arsenic had a higher baseline fasting 
blood glucose, which was resolved at the end of the 8 weeks and no difference was 
observed (Figure 2.7a). While the baseline fasting blood glucose in our male 
heterozygote 10x treatment group started out lower than the other initial blood glucose 
measurements, this trend remained constant during the duration of exposure (Figure 
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2.7b). These results demonstrate that even with differences in baseline glucose tolerance, 
arsenic did not cause reduced glucose tolerance during the course of exposure.  
We also measured change in glucose tolerance through analyzing the area under 
the curve of the glucose tolerance test (Figure 2.7c and 2.7d). There was no significant 
difference in any genotype based on treatment group, although the male heterozygotes 
begin with a slightly higher AUC and end with this intact. These results do not support 
our hypothesis that arsenic will decreased glucose tolerance. 
 In the female OGTT, there was a significant difference in the peak of the curve in 
the 12-week measurement between wild-type control and heterozygote controls (Figure 
2.8c). Another significant difference occurred in the heterozygote dose response at the 
baseline glucose tolerance test (Figure 2.8d). The 10x treatment group was significantly 
lower than the 1x treatment group at the 30-minute time point. However, this did not 
continue and is no longer visible in the 8-week (Figure 2.8e) or 12-week (Figure 12.8f) 
curves. These finding show that while at certain time points, arsenic may cause slight 
changes in glucose tolerance, over the duration of chronic exposure this change does not 
persist and lead to sustained reduced glucose tolerance.  
 Breaking down the OGTT, we did see a significant difference in the fasting blood 
glucose at 12 weeks between the wild-type and heterozygote controls shown by an 
increase from 100 mg/dl in the controls to 120 mg/dl in the heterozygotes (Figure 2.9a). 
No changes in the fasting blood glucose in the heterozygote dose response were observed 
thereby supporting the idea that glucose tolerance is not altered by arsenic exposure 
(Figure 2.9b). While there appeared to be a slight difference in AUC measurements in the 
female heterozygote 1x treatment group at 4 weeks, this did not continue through to 12 
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weeks (Figure 2.9c). This change was also not exacerbated by increasing the exposure to 
arsenic (Figure 2.9d), further demonstrating that arsenic does not have an effect on 
glucose tolerance in the wild-type or heterozygote females.  
2.3.4 Histology 
We expected that because there were differences in weight change, then there 
would also be changes in adipose tissue morphology. Figure 2.10 presents representative 
histological images of each treatment group. We analyzed these images to quantitate 
adipocyte size and diameter in both males (Figure 2.11) and females (Figure 2.12). In the 
male heterozygotes exposed to arsenic, there was an increase in size and diameter of 
adipocytes analyzed, but this only applied to the 1x arsenic concentration and the change 
was not significant (Figure 2.11a and b). At 10x, the male heterozygotes had reduced size 
and diameter compared to the control heterozygotes, although again, the difference was 
not significant (Figure 2.11c and d). This differs from the females, where there were no 
changes in adipocyte size present (Figure 2.12). Overall, while we have demonstrated 
that there were changes in weight gain, fat mass and lean mass these results did not 
translate into the expected changes in adipose tissue morphology. 
2.3.5 Gene expression 
To examine the effects of arsenic on inflammation, which can alter the 
inflammatory state both locally in adipose tissue and systemically, we examined the 
expression of pro- and anti-inflammatory adipokines in males (Figure 2.13) and females 
(Figure 2.14).  
In wild-type males, arsenic had no significant effect on adipokine expression of 
TNF-α, leptin or adiponectin However, it appears to increase adiponectin and decrease 
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TNF-α in the arsenic-treated group compared to controls. This differs from the 
heterozygotes, where arsenic significantly increases leptin expression in the 1x treatment 
group (Figure 2.13e), which is not exacerbated by increasing the arsenic exposure to 10x. 
In fact, the 10x treatment in heterozygotes appears to reduce the expression of 
adiponectin, leptin and TNF-α compared to the 1x treatment, showing that increasing 
arsenic exposure may actually diminish total immune response. 
In female wild-type mice exposed to arsenic, there was a significant increase in 
leptin expression (Figure 2.14b). Also while not significant, TNF-α expression appears to 
be increased, (Figure 2.14c). In the heterozygotes, arsenic had no significant effect on 
adipokine expression, although the 10x increased leptin and TNF-α expression compared 
to both control and 1x exposures (Figure 2.14e and f). These results demonstrated that 
even if arsenic does not have a significant effect on the immune system, depending on 
individual genetics the immune response will be different.  
2.3.6 Triglycerides 
Because of the effects of arsenic on weight, we wanted to determine whether this 
also altered triglyceride levels in various tissues throughout the body. We chose to 
examine tissues that have been demonstrated to accumulate arsenic or be affected by 
arsenic exposure, including the heart, kidney, liver and muscle. 
 In the males, arsenic had no significant effect on triglyceride levels (Figure 2.15), 
however the 1x treatment group appeared to raise triglyceride levels slightly in the liver 
and muscle, the 10x treatment group was reduced to levels very similar to control. In the 
females, arsenic had no significant effect on triglyceride levels (Figure 2.16), while it 
appeared that in the heterozygote group, 1x arsenic treatment increases heart and kidney 
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triglycerides, the 10x treatment reduces these levels back to comparable to control. There 
are significant genotypic differences present in the females in both the liver and heart 
triglycerides (Figure 2.16c and d). The heterozygote females have higher triglyceride 
levels in both organs, which may be attributed to them having larger lean, fat and total 
mass compared to the wild-type mice, but overall arsenic had no impact on organ 
triglyceride levels.  
2.4 Discussion 
The current literature is undecided as to whether arsenic plays a role in the 
development of type 2 diabetes, especially at lower doses. We, therefore, sought to 
examine the effects of arsenic on body composition, glucose tolerance and cytokine 
expression in non-susceptible mice to determine whether these may contribute to 
increased risks for the development of type 2 diabetes. Our results demonstrated that 
there were no indicators of diabetes developing in these animals, but other changes that 
could lead to increased susceptibility were observed such as an increase in systemic and 
localized inflammation, which we will evaluate further in later studies.  
Male and female wild-type mice are representative of a non-susceptible 
population; however, type 2 diabetes can be induced when fed a high fat diet. We 
examined whether arsenic would change the body composition in these mice, leading to 
increased fat mass, decreased glucose tolerance and increased inflammation – all of 
which could lead to the progression of diabetes. However, we found at the level of 
arsenic used in these studies was insufficient to induce changes in glucose tolerance, but 
it was enough to induce changes in weight gain and changes in inflammation in adipose 
tissue. 
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Arsenic alone is not a known inducer of obesity. In animal studies, arsenic 
exposure, especially at higher levels, caused reduced water and food intake leading to a 
slower, but not significantly different, increase in weight (D S Paul et al., 2008; David S. 
Paul, Hernandez-Zavala, et al., 2007). In our animal model, both males and females 
demonstrated that weight gain was increased during the period of arsenic exposure. One 
of the major differences when comparing our study to others is the route of arsenic 
exposure. Our mice were exposed every other day by oral gavage, where drinking water 
exposures were used for other studies. The prolonged exposure may cause a decrease in 
appetite that would damped weight gain during exposure periods. 
The differences in body composition between female wild-type and heterozygote 
controls were very prominent compared to males. The heterozygote females had a greater 
increase in lean, fat and total mass from baseline to 12 weeks old when compared to the 
wild-type females The only significant change in body composition we have reported that 
is directly related to arsenic exposure is between the female heterozygote control and the 
10x treatment group, where at this higher concentration of arsenic, we saw a decrease in 
lean and total mass from 4-8 weeks. This however was no longer present at the 
conclusion of the study, demonstrating that the body may be able to correct for some 
changes over time even when challenged with a toxicant such as arsenic at low levels.   
When comparing these to the adipose tissue histology, there was no difference in 
adipocyte size or diameter in the arsenic treatment of males or females. Typically, in an 
obese individual, the adipose tissue morphology will change. Adipocytes become larger 
as obesity increases but because there was no difference in weight, only an increase in fat 
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mass, this may be the reason for no difference. Different results may have been obtained 
if other fat pads (visceral, subcutaneous) were examined for comparison.  
While we may have reported differences in weight change in our treatment 
groups, there were no changes in fasting blood glucose over the 12-week period. We 
evaluated glucose tolerance by an OGTT, which we examined by analyzing the fasting 
blood glucose and area under the curve. Typically, in a diabetic individual the fasting 
blood glucose and area under the curve measurement will be much higher than a non-
diabetic. In previous studies examining the effects of arsenic on glucose tolerance using 
mice, changes in blood glucose tolerance were reported, but the concentration and 
original form and route of arsenic exposure varied greatly (Huang et al., 2015; Liu et al., 
2014; D S Paul et al., 2008; David S. Paul, Harmon, et al., 2007; David S. Paul et al., 
2011; S. Rahman et al., 2016; Rodríguez et al., 2016). This may mean that the lower 
levels of arsenic we used might not alter glucose tolerance over a short period of time. 
Because of the changes in body weight, we wanted to determine whether there 
was a concurrent affect in local inflammation in the adipose tissue. We examined three 
adipokines that have different effects on the local and systemic immune system: 
adiponectin (an anti-inflammatory cytokine), TNF-α and leptin, which are all pro-
inflammatory cytokines. In the wild-type males, we observed a 2-fold increase in 
adiponectin, which shows that while there were no significant changes in body 
composition, arsenic induced a slight suppression in the local immune response. In the 
male heterozygotes, which did have changes in body composition, leptin expression was 
significantly upregulated 2-fold in the 1x treatment group or slightly increased in the 10x 
treatment group. 
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 In females the inflammatory response was very different. In the wild-type 
exposed to arsenic, there was a significant 2-fold increase in adipose tissue expression of 
leptin accompanied by a slight increase in TNF-α, which can be attributed to this group 
having a larger change in weight over the exposure time. The female heterozygotes had a 
mixed immune response, with 1x arsenic treated mice having a 2-fold increase in 
adiponectin and TNF-α and the 10x treatment group having a 2-fold increase in leptin 
and TNF-α, although none of the changes were significant. Both of these treatment 
groups had very similar weight changes, so the differences in response must be the result 
of the concentrations of arsenic used. The increase in arsenic in the 10x group may have 
been sufficient to overstimulate the pro-inflammatory response and reduce the expression 
of adiponectin. 
 We chose to examine triglycerides because of the varying changes arsenic caused 
in body composition. All of the organ triglyceride levels measured in this experiment 
have been shown to be increased in diabetic cases (Christoffersen et al., 2003; Kelley & 
Goodpaster, 2001; Shimomura, Bashmakov, & Horton, 1999; Sun, 2002). While we saw 
minimal indicators of diabetes, the majority of the changes in these organ triglycerides 
can be attributed to the changes in fat or body weight over the duration of treatment. So 
by modifying body composition, arsenic also affected triglyceride content in different 
organs in the body. 
 Overall, our study demonstrated that the effects caused by arsenic differ, not only 
by concentration of exposure and sex but by genotype as well. None of the systems 
affected by arsenic responded similarly within these different models. In the future, 
adding in the db/db genotype will allow us to determine how arsenic affects an individual 
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that will genotypically develop type 2 diabetes at an early age. It would also be beneficial 
to compare this study to a diet-induced diabetes model using the same mice to determine 
whether our parameters would change as obesity increases. Adding these two pieces of 
the puzzle would allow us to not only compare the mechanisms by which arsenic affects 
a non-susceptible individual to a diet-induced obese individual but also affects in a 
genetically-induced obese individual.  
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Table 2.1. Real-time PCR Primer List.  
ID Forward 5’-3’ Reverse 5’-3’ 
Adiponectin CTACTGCAACATTCCGGGAC TGCGAATATTGTGAAGCCCC 
Leptin GACATTTCACACACGCAGTC GAGTCATGCCTTTGGATGGG 
TNF-α AGCACAGAAAGCATGATCCG CTACAGGCTTGTCACTCGAA 
RPLP0 CCTGAAGTGCTCGACATCAC GCGCTTGTACCCATTGATGA 
Abbreviations: Tumor necrosis factor alpha – TNF-α, Ribosomal protein lateral stalk 
subunit P0 – RPLP0 
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Figure 2.1 Experimental layout. Starting at the age of 4 weeks, mice will begin arsenic 
exposure and weighing every other day (EOD). This will also be the baseline oral glucose 
tolerance test (OGTT) and dual-energy X-ray absorptiometry (DEXA) scan. These tests 
will be repeated at week 8 and week 12, when the study will conclude. 
 
 
 
 
• Baseline 
DEXA 
• Baseline 
OGTT 
• Begin 
Dosing EOD 
• Weigh EOD 
 
• 8 Week 
DEXA 
• 8 Week 
OGTT 
 
• 12 Week 
DEXA 
• 12 Week 
OGTT 
• End Study 
 
4 Weeks 8 Weeks 12 Weeks 
  
5
0
 
 
Figure 2.2. Change in weight in male wild-type and heterozygotes after 8 weeks of arsenic exposure. Mean weight change for 
each genotype (WT – wild-type, Het – heterozygote) over time. A) Compared to wild-type controls, the mean change in weight for het 
male controls and iAs 1x was significantly greater. B) Increase in arsenic exposure did not alter average change in weight for control, 
1x, and 10x hets. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using linear 
regression and is indicated as * (p<0.05). 
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Figure 2.3. Change in weight in female wild-type and heterozygotes after 8 weeks of arsenic exposure. Mean weight change for 
each genotype (WT – wild-type, Het – heterozygote) over time. A) Compared to wild-type controls, the mean change in weight for 
iAs-treated WT and het females was significantly greater over the 8-week dosing period. B) Increase in arsenic exposure did not 
increase the mean change in weight for control, 1x, and 10x hets. Data are represented as the mean of each treatment group ± SEM 
Statistical significance was assessed using linear and is indicated as * (p<0.05). 
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Figure 2.4. Mean change in body composition in males. Change in DEXA scan results from male WT and hets at 4-8 weeks (A and 
B) and from 4-12 weeks (C and D) after arsenic exposure. Arsenic had no effect on body composition, however the lean mass in the 
male het control from 4-12 weeks had a significantly greater increase compared to wild-type control. Data are represented as the mean 
of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by Tukey’s multiple comparison 
test and is indicated as * (p<0.05). 
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Figure 2.5. Mean change in body composition in females. Change in DEXA scan results from female WT and heterozygotes at 4-8 
weeks (A and B) and from 4-12 weeks (C and D) after arsenic exposure. From 4-8 weeks, 10x arsenic significantly reduced the 
change in lean and total mass in female hets compared to control, however this did not persist until 12 weeks. From 4-12 weeks, 
arsenic had no effect on body composition, however the control female hets had a greater increase in lean, fat and total mass compared 
to wild-type controls. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using 
linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05). 
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Figure 2.6. Male oral glucose tolerance test (OGTT) curves. Change in glucose tolerance during oral glucose tolerance test in male 
wild-type and heterozygotes at 4 (A, B), 8 (C, D) and 12 (E, F) weeks old after arsenic exposure. While significant differences were 
present at the 15-minute time point in the male hets at the baseline OGTT measurement, no changes were persistent through the entire 
dosing period. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using ANOVA 
followed by Tukey’s multiple comparison test and is indicated as * (p<0.05). 
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Figure 2.7. Changes in male glucose tolerance. Change in fasting blood glucose (A and B) and area under the curve (C and D) in 
male wild-type and heterozygous mice after 8 weeks of arsenic exposure. Neither arsenic nor genotype significantly affected FBG or 
AUC measurements. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using 
linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05). 
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Figure 2.8. Female oral glucose tolerance test (OGTT) curves. Change in glucose tolerance during oral glucose tolerance test in 
female wild-type and heterozygous mice at 4 (A, B), 8 (C, D) and 12 (E, F) weeks old after arsenic exposure. While a significant 
increase in blood glucose are present at the 30-minute time point in the female 1x hets at baseline, this difference is not exacerbated by 
arsenic over the dosing period. Arsenic did significantly increase the peak at 15 minutes in the 12 week OGTT in female het control 
compared to wild-type control. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed 
using ANOVA followed by Tukey’s multiple comparison test and is indicated as * (p<0.05). 
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Figure 2.9. Changes in female glucose tolerance. Change in fasting blood glucose (A and B) and area under the curve (C and D) in 
female wild-type and heterozygous mice after 8 weeks of arsenic exposure. While arsenic exposure did not significantly affect FBG or 
AUC measurements, wild-type controls had a lower fasting blood glucose at 12 weeks compared to het controls. Data are represented 
as the mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by Tukey’s 
multiple comparison test and is indicated as * (p<0.05).
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Figure 2.10. Reproductive adipose tissue histology. H&E sections from males (column 1) and females 
(column 2). A) WT Control B) WT iAs C) Het Control D) Het iAs (1x) E) Het iAs (10x). Images are at 4x 
magnification. Statistical significance was assessed using linear regression followed by Tukey’s multiple 
comparison test and is indicated as * (p<0.05).
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Figure 2.11. Arsenic does not significantly alter male reproductive adipose tissue histology. Software analysis of reproductive fat 
histological sections reveal that there are no significant differences in adipocyte diameter or area in wild-type or het males. Graphs 
represent the male adipocyte area (A and B) and diameter (C and D) analyzed using Adiposoft software and data are represented as the 
mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by Tukey’s multiple 
comparison test and is indicated as * (p<0.05). 
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Figure 2.12. Arsenic does not significantly alter female reproductive adipose tissue histology. Software analysis of reproductive 
fat histological sections reveal that there are no significant differences in adipocyte diameter or area in wild-type or het females. 
Graphs represent the female adipocyte area (A and B) and diameter (C and D) analyzed using Adiposoft software and data are 
represented as the mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by 
Tukey’s multiple comparison test and is indicated as * (p<0.05). 
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Figure 2.13. Arsenic significantly increases leptin expression in male heterozygote reproductive adipose tissue. Graphs A, B and 
C represent wild-type vs heterozygote gene expression and graphs D, E and F represent heterozygote dose response gene expression. 
Arsenic exposure significantly increased leptin expression in reproductive adipose tissue compared to control, but this was not 
exacerbated by 10x exposure. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed 
using linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05). 
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Figure 2.14. Arsenic significantly increases leptin expression in female wild-type reproductive adipose tissue. Graphs A, B and 
C represent wild-type vs heterozygote gene expression and graphs D, E and F represent heterozygote dose response gene expression. 
Arsenic exposure increases expression of leptin in wild-type females exposed to arsenic compared to controls. Data are represented as 
the mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by Tukey’s multiple 
comparison test and is indicated as * (p<0.05). 
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Figure 2.15. No differences present in male organ triglycerides. Graphs A-D represent wild-type vs heterozygote triglycerides in 
different organs and graphs E-H represent heterozygote dose response triglycerides in different organs. There are no significant 
changes in triglyceride levels in the heart, kidney, liver or muscle caused by arsenic exposure or genotype differences. Data are 
represented as the mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by 
Tukey’s multiple comparison test and is indicated as * (p<0.05). 
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Figure 2.16. Female heterozygote controls have higher levels of liver and muscle triglycerides compared to wild-type controls. 
Graphs A-D represent wild-type vs heterozygote triglycerides in different organs and graphs E-H represent heterozygote dose 
response triglycerides in different organs. Arsenic exposure did not change triglyceride levels in the heart, kidney, liver or muscle. 
However, female het controls had significantly higher levels of liver and muscle triglycerides compared to wild-type controls. Data are 
represented as the mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by 
Tukey’s multiple comparison test and is indicated as * (p<0.05).
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Chapter 3 – Arsenic and Inflammation 
3.1 Introduction  
Arsenic, a ubiquitous element, is a known toxin in its inorganic form. Humans are 
exposed to about 50 µg/day, 3.5 µ/day coming from inorganic sources in food and water 
(ATSDR, 2013). Because arsenic is a well-known carcinogen, in an attempt to reduce 
levels of exposure the amount of arsenic in public drinking water is very highly 
regulated, with a relatively recent reduction in action level from 50 µg/L to 10 µg/L by 
the EPA in 2001 (ATSDR, 2013). Besides cancer, arsenic is known to affect a number of 
different organ systems and has been linked to cardiovascular disease, type 2 diabetes and 
immunological disorders (Mandal & Suzuki, 2002).  It has been demonstrated that at 
higher concentrations (>500 µg/L), arsenic may increase susceptibility to type 2 diabetes, 
but at lower concentrations the results are inconclusive (Huang et al., 2011; Navas-Acien 
et al., 2006). The effects of arsenic on inflammation in humans and mice have been 
extensively reviewed by Dangleben et al., Mandal and Suzuki, and Tobergte and Curtis 
(2013; 2002; 2013). According to these sources, arsenic can alter gene expression, 
immune cell population, and ROS production that can lead to either a range of different 
consequences from a suppressed immune system to a pro-inflammatory immune state, 
however the results will vary based on the concentration of arsenic in question. While the 
majority of studies have focused on higher levels of arsenic exposure and the effects on 
the immune system, there is still a lot unknown about how low-level arsenic exposure can 
affect the immune response. 
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When considering the effects of arsenic on inflammation, the baseline 
inflammatory profile is an important component to be considered. In lean individuals, 
there is a balance in the inflammatory state. However, as BMI increases, the 
inflammatory profile shifts towards a more pro-inflammatory state that is both local in 
the adipose tissue and systemic (Mosser & Edwards, 2008). Thus, it is important to 
determine whether arsenic affects metabolic diseases, such as type 2 diabetes, where 
changes in inflammation may play a vital role in the progression of the disease. In our 
study we propose to examine the effects of arsenic on the immune system in both sexes 
of two lean mouse strains – C57BL/6 and db/+ at low (50 µg/kg) and high (500 µg/kg) 
levels of arsenic. This will allow us to begin to determine whether there are sex 
differences in the immune response induced by arsenic exposure and to examine the role 
of genotype in these lean mice. We will evaluate inflammation by examining systemic 
cytokine profiles and organ-specific gene expression. This will be compared to the 
overall change in body composition in these mice to determine whether the inflammatory 
profile changes as a result of arsenic exposure or due to changes in the mouse fat mass. 
Based on current literature and the results at high levels of arsenic exposure, we 
hypothesize that in these lean mice, arsenic will increase systemic and local 
inflammation. 
3.2 Methods 
3.2.1 Animals 
Male and female B6.BKS(D)Leprdb/J heterozygote mice were bred and housed at 
the University of South Carolina Animal Resource Facility. Offspring of the heterozygote 
x heterozygote cross were genotyped by RT-PCR followed by a restriction digest for the 
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Leptin gene at weaning.  The primer sequences were forward: 5’-
AGAACGGACACTCTTTGAAGTCTC-3’; and reverse: 5’-
CATTCAAACCATAGTTTAGGTTTGTGT-3’. PCR products were digested using RsaI 
enzyme, which cleaved sequences into one 135 base pair band or 27, 108 and 135 base 
pair bands representing wildtype or heterozygous genotypes, respectively. Once 
genotypes, animals were grouped into control, 1x inorganic arsenic (AsCl3 - Alfa Aesar, 
50µg/kg) or 10x inorganic arsenic (500µg/kg) and were gavaged every other day. 
Weights were recorded every other day starting when the mice were 4 weeks old, and 
every 4 weeks an oral glucose tolerance test (OGTT) and Dual Energy X-ray 
Absorptiometry (DEXA) scan were performed. Animals were maintained on a 12:12 hour 
light cycle and given food and water ad libitum. At 12 weeks, animals were sacrificed for 
tissue collection using isoflurane overdose followed by cervical dislocation. Principles of 
laboratory animal care were followed and the Institutional Animal Care and Usage 
Committee of the University of South Carolina approved all experiments.  
3.2.2 Tissue collection  
Mice were euthanized at 12 weeks of age for tissue collection. Blood was 
collected by cardiac puncture and serum separated for cytokine analysis. Reproductive 
adipose tissue was collected for histology, preserved for 24 hours in 4% 
paraformaldehyde and then transferred to 70% ethanol before histology, or snap frozen 
on dry ice and stored at -80ºC for triglyceride, protein, and RNA analysis. Spleen, liver, 
kidney, thigh muscle and heart were also snap frozen and stored at -80ºC for protein and 
RNA analysis. 
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3.2.3 Cytokine analysis  
Spleen and serum cytokines were measured by multiplex bead-based assay (Bio-
Plex, Bio-Rad) according to manufacturer’s protocol for the following cytokines: 
interleukin (IL)-1β, IL-4, IL-6, IL-10, IL-13, interferon (IFN)-γ, granulocyte macrophage 
colony-stimulating factor (GMCSF) and tumor necrosis factor (TNF)-α. Limits of 
detection were as follows in the spleen (in pg/ml): IL-1β=28.11, IL-4=3.59, IL-6=1.01, 
IL-10=11.03, IL-13=53.43, IFN-γ=14.09, GMCSF=9.37 and in the serum (in pg/ml): IL-
1β=60.52, IL-6=1.27 and TNF-α=53.82. Standard curves were generated in triplicate. 
Cytokine measurements below the limit of detection were assigned a value of the limit of 
detection/√2 for statistical analysis and plotting. TNF-α levels were measured in 
homogenized spleen using ELISA kits (eBioScience) according to the manufacturer’s 
instructions, with a limit of detection of 8 pg/mL. 
3.2.4 Gene expression  
RNA was isolated from reproductive adipose tissue according to the 
manufacturer’s protocol (Bioline Isolate RNA kit). RNA was converted to cDNA using 
SensiFAST cDNA synthesis kit according to manufacturer’s protocol (Bioline). Real-
time PCR was then performed on 100ng of cDNA using SensiFAST SYBR (Bioline) and 
10µM of designed and validated primers according to manufacturer’s protocol. Custom 
primers (Table 3.1) were designed for each target using Primer Blast Search (NCBI) and 
purchased from Integrated DNA Technologies (IDT) for qPCR. Gene expression patterns 
for each gene were normalized to the expression of the housekeeping gene RPLP0 and 
quantified using the ΔΔCT method. 
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3.3 Statistics 
All statistical analyses were carried out using Stata for linear regression and 
Tukey’s post-test. The n for each treatment group were as follows: male wild-type control 
(n=5), male wild-type arsenic (n=4), male heterozygote control (n=11), male 
heterozygote arsenic 1x (n=8), male heterozygote arsenic 10x (n=3), female wild-type 
control (n=6), female wild-type arsenic (n=5), female heterozygote control (n=9), female 
heterozygote arsenic 1x (n=6), female heterozygote arsenic 10x (n=3), unless otherwise 
noted. Three mice were excluded from all analyses as they were outliers in more than 3 
different categories analyzed. Data are expressed as means ± SEM. Regression analysis 
were performed to compare exposure, genotypic, and sex differences. A p-value of <0.05 
was considered statistically significant.   
3.4 Results 
3.4.1 Effect of arsenic on fat mass 
 We predicted that arsenic exposure would cause changes in body composition that 
would affect systemic inflammation. In order to determine whether the effects on the 
immune system were caused by change in body fat or by arsenic, we first plotted the 
change in body fat from baseline (4 weeks) to 12 weeks of age for both males and 
females (Figure 3.1). While the male heterozygous animals appear to have a greater 
change in body fat after 8 weeks of 1x arsenic exposure, the change was not significant. 
The only difference found to be significant based on genotype was between female wild-
type control and female heterozygotes, indicated by an increase in fat mass from baseline 
in the heterozygotes compared to wild-type (Figure 3.1). 
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3.4.2 Effect of arsenic on serum cytokines 
To determine the effect of arsenic on systemic inflammation, we chose to 
examine the serum cytokines. Both TNF-α and IL-1β were below the limit of detection, 
and therefore excluded. There was no significant difference in IL-6 in circulation based 
on treatment group or genotype for males or females (Figure 3.2), however there were 
sextypic differences in the heterozygotes. In the males exposed to 10x arsenic, there is a 
large increase in IL-6 in circulation, but in females as arsenic exposure increases in the 
heterozygotes IL-6 in circulation decreases, demonstrating that males may have more 
proinflammatory cytokines in circulation in response to arsenic exposure.  
3.4.3. Effects of arsenic on spleen cytokines 
 To further examine the effects of arsenic on systemic inflammation, and because 
cytokines are short-lived in circulation, we also evaluated cytokine levels in the spleen. In 
the male heterozygotes, IFN-γ was decreased in the 1x arsenic treatment group, but this is 
not present or amplified in the 10x treatment group (Figures 3.3 and 3.4). This differed 
greatly from the response in the females, where in the wild-type mice IFN-γ and IL-1β 
were significantly increased (Figure 3.5). In the female heterozygotes, IL-13 was 
significantly decreased between 1x and 10x treatment groups but IL-10 and IL-4 were 
significantly increased from 1x-10x treatment groups (Figure 3.6). This demonstrated that 
in females, depending on genotype, arsenic can either induce a more proinflammatory 
response in circulating cytokines or anti-inflammatory response. 
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3.4.4 Effect of arsenic on local inflammation 
 We wanted to examine the effects of arsenic exposure on local inflammation, and 
to do this we chose to evaluate changes in macrophage expression. With changes in body 
composition, there are changes in macrophage populations. As fat mass increases, there is 
a shift from balanced M1/M2 macrophage phenotypes to a pro-inflammatory M1 
phenotype. In adipose tissue, this is typically correlated with an increase in macrophage 
accumulation in tissue (Kathryn, Wellen, & Gokhan, 2003). In Figures 3.7 and 3.8, we 
did not see a change in expression of either inducible nitric oxide synthase (iNOS) (M1), 
arginase (M2), or CCL2 (macrophage recruitment) in either males or females after 
arsenic exposure. However, there were overall differences in the heterozygous males 
exposed to 10x arsenic; while not significant, arginase, iNOS, and CCL2 were reduced 
compared to the 1x treatment group (Figure 3.7). There were also non-significant 
sextypic differences, as CCL2 in 1x arsenic-exposed heterozygous males was increased 
from control, where in 1x arsenic-exposed heterozygous females CCL2 was reduced.  
 We chose the same method of assessment in the spleen, however, unlike in the 
adipose tissue, male heterozygotes in the 10x treatment group showed an increase in 
expression in both iNOS and arginase (Figure 3.9). There were minimal changes in 
expression in either gene in the wild-type males, indicating there were no changes in 
macrophage population. Females had no significant change in either iNOS or arginase 
based on exposure to arsenic (Figure 3.10). However, when examining differences 
between the two genes, female wild-type mice had a decrease in arginase and an increase 
in iNOS when exposed to arsenic. 
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 Finally, we wanted to evaluate changes in macrophage populations in the liver, as 
this is the primary organ for detoxification. We saw no significant changes in male 
(Figure 3.11) or female (Figure 3.12) liver expression of arginase or iNOS with arsenic 
exposure. While not significant, there is a large increase in the expression of iNOS in the 
male heterozygotes exposed to 10x arsenic. This differs from the female heterozygotes 
exposed to 10x arsenic, where there is a decrease in iNOS expression.  
3.5 Discussion 
 Overall, there were differences in inflammation caused by arsenic exposure in 
both sexes, genotypes and treatment groups. Most studies focusing on the effects of 
arsenic exposure are limited in scope to the effects on the development of type 2 diabetes. 
Here, we present a case for low-dose arsenic exposure, similar to exposure levels in the 
United States, wherein arsenic is not diabetogenic but induces changes in the immune 
response. We also present novel male and female data, since the majority of studies 
examining the effects of arsenic have been limited to only males.  
 In circulating cytokines, males and females exhibited very different responses 
depending on genotype. Where male heterozygotes had a decrease in IFN-γ when 
exposed to 1x arsenic, female wild-type mice had an increase in IFN-γ. In female 
heterozygotes, when increasing arsenic exposure from 1x to 10x arsenic there is a drastic 
change in cytokine profile with an increase in IL-4 and IL-10 and a decrease in IL-13, 
which demonstrates changes in the anti-inflammatory environment. Overall, the 
circulating inflammatory environments for each of these treatment groups is very 
different. Where wild-type males were not affected, the change in male heterozygotes 
indicates a decrease in inflammation. In the female wild-type mice, arsenic increased 
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both IFN-γ and IL-1β, which are both pro-inflammatory cytokines. For female 
heterozygotes, as arsenic concentration increased, there was an increase in anti-
inflammatory cytokines. This is opposite of what we would have expected based on the 
change in fat mass in the females, as the heterozygotes had the greatest increase in fat 
mass. Based on current literature, this increase in fat mass in this genotype should have 
had more pro-inflammatory cytokines in circulation, suggesting that the changes 
exhibited in systemic inflammation were arsenic driven, not obesity driven.  
 To examine inflammation at a local level, we chose to evaluate gene expression 
changes in organs that are affected by arsenic exposure: adipose tissue, liver and spleen. 
These three tissues accumulate arsenic, and are vulnerable to exposures (ATSDR, 2013). 
We hypothesized that since arsenic is typically an inducer of inflammation, the 
macrophage populations in these tissues would shift from a balanced M1/M2 population 
toward a primarily M1 population. To test this hypothesis, we chose three genes, 
arginase, iNOS and CCL2 to determine the effects of arsenic on macrophage populations. 
The primary organ affected was the spleen of heterozygote males. In this group, as 
arsenic exposure increased, the expression of iNOS and arginase increased. This could be 
due to an increase in total macrophage population. Female spleens, despite the increased 
pro-inflammatory cytokines in circulation, were not affected at the tissue level.  
 Here we have presented that, depending on sex and genotype, arsenic has very 
different effects on the immune system. Both of these mouse models represent a non-
susceptible population for diabetes, and while there was a significant difference in fat 
mass in females based on genotype, all of the changes observed are correlated with 
arsenic exposure. These findings will inform future analysis of arsenic and the 
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development of diabetes in a susceptible model. While we cannot link these low levels of 
arsenic to diabetes in our models, we can say that low-dose arsenic exposures can have 
significant impacts on the immune system that warrant further exploration. 
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Table 3.1. Real-time PCR Primer list.  
ID Forward 5’-3’ Reverse 5’-3’ 
CCL2 CAGCAGGTGTCCCAAAGAAG ACCTTAGGGCAGATGCAGTT 
iNOS GAAGTTCAGCAACAACCCCA TTCAAGATAGGGAGCTGCGA 
Arginase CCCTGCCAATCATGTTCCTG GAGAAAGGGGCTCCGACTAT 
RPLP0 CCTGAAGTGCTCGACATCAC GCGCTTGTACCCATTGATGA 
Abbreviations: Chemokine ligand 2 – CCL2, Inducible nitric oxide synthase – iNOS, 
Ribosomal protein lateral stalk subunit P0 – RPLP0 
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Figure 3.1. Arsenic does not significantly alter change in fat mass. Change in fat mass from 4 weeks to 12 weeks old in male and 
female mice. Female wild-type mice have a significantly lower change in fat mass than female heterozygotes without arsenic exposure. 
Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed 
by Tukey’s multiple comparison test and is indicated as * (p<0.05). 
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Figure 3.2. Arsenic has no effect on serum IL-6 levels. Serum cytokine profile of male and female wild-type and heterozygous 
mice. There were no significant differences present in IL-6 levels in circulation in either males or females. Cytokines were measured 
by Bio-Plex. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using linear 
regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05). 
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Figure 3.3. Arsenic reduces IFN-γ in spleen of male heterozygotes. Spleen cytokine analysis of male wild-type and heterozygotes 
after 8 weeks of arsenic exposure. IFN-γ was significantly reduced in male heterozygotes. Cytokines were measured by elisa and the 
results calculated as pg/g spleen tissue. Data are represented as the mean of each treatment group ± SEM. Statistical significance was 
assessed using linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05). 
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Figure 3.4. Increase in arsenic exposure does not affect IFN-γ in male heterozygotes. Spleen cytokine analysis of male 
heterozygotes after 8 weeks of arsenic exposure. IFN-γ was reduced in male heterozygotes in the 1x arsenic treatment group, but this 
was not exacerbated by increasing exposure levels. Cytokines were analyzed by elisa and the results calculated as pg/g spleen tissue. 
Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using linear regression 
followed by Tukey’s multiple comparison test and is indicated as * (p<0.05). 
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Figure 3.5. Arsenic exposure increases IL-1β and IFN-γ in wild-type females. Spleen cytokine analysis of female wild-type and 
heterozygotes after 8 weeks of arsenic exposure. Female wild-type mice had a significant increase in IFN-γ and IL-1β caused by 
arsenic exposure. Cytokines were measured by elisa and the results calculated as pg/g spleen tissue. Data are represented as the mean 
of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by Tukey’s multiple comparison 
test and is indicated as * (p<0.05). 
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Figure 3.6. Increase in arsenic exposure affects female heterozygote spleen cytokines. Spleen cytokine analysis of female 
heterozygotes after 8 weeks of arsenic exposure. Increase from 1x to 10x arsenic exposure increased IL-10 and IL-4 concentration, but 
decreased IL-13 concentration. Cytokines were measured by elisa and the results calculated as pg/g spleen tissue. Data are represented 
as a mean of each treatment group ± SEM. Statistical significance was assessed using linear regression followed by Tukey’s multiple 
comparison test and is indicated as * (p<0.05). 
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Figure 3.7. Arsenic exposure does not affect adipose tissue cytokine expression in males. In male adipose tissue, arginase, iNOS, 
and CCL2 expression was determined by RT-PCR. Arsenic did not have an effect on the expression of any analyzed genes. All data 
were normalized to RPLP0. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed 
using linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05). 
  
8
3
 
 
Figure 3.8. Arsenic exposure does not affect adipose tissue cytokine expression in females. In female adipose tissue, arginase, 
iNOS, and CCL2 expression was determined by RT-PCR. Arsenic did not significantly alter any of the analyzed genes. All data were 
normalized to RPLP0. Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using 
linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05). 
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Figure 3.9. Increase in arsenic exposure affects macrophage gene expression in male heterozygote spleens. Male heterozygotes 
had an increase in arginase and iNOS expression in the spleen after 8 weeks of 10x arsenic exposure. Arginase and iNOS expression 
was determined by RT-PCR. All data were normalized to RPLP0. Data are represented as the mean of each treatment group ± SEM. 
Statistical significance was assessed using linear regression followed by Tukey’s multiple comparison test and is indicated as * 
(p<0.05). 
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Figure 3.10. Arsenic exposure does not affect spleen cytokine expression in females. In females no change was observed in the 
spleen after 8 weeks of 10x arsenic exposure. Arginase and iNOS expression was determined by RT-PCR. All data were normalized to 
RPLP0. Data are represented as a mean of each treatment group ± SEM. Statistical significance was assessed using linear regression 
followed by Tukey’s multiple comparison test and is indicated as * (p<0.05). 
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Figure 3.11. Arsenic exposure does not affect male macrophage gene expression in the liver. In males, there was no change in 
gene expression in the liver after 8 weeks of 10x arsenic exposure. Arginase and iNOS expression was determined by RT-PCR. All 
data were normalized to RPLP0. Data are represented as a mean of each treatment group ± SEM. Statistical significance was assessed 
using linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05). 
  
8
7
 
 
Figure 3.12. Arsenic exposure does not affect female macrophage gene expression in the liver. In females, there was no change in 
gene expression in the liver after 8 weeks of 10x arsenic exposure. Arginase and iNOS expression was determined by RT-PCR. All 
data were normalized to RPLP0. Data are represented as the mean of each treatment group ± SEM. Statistical significance was 
assessed using linear regression followed by Tukey’s multiple comparison test and is indicated as * (p<0.05). 
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Chapter 4 – Arsenic and Macrophages 
4.1 Introduction 
Arsenic is a ubiquitous element found in the earth’s crust that can be naturally 
occur in organic and inorganic forms. Typical arsenic exposure is about 50 µg/day, with 
about 3.5 µg/day from inorganic sources and the remainder from non-toxic organic 
sources (ATSDR, 2013). The main exposures to inorganic arsenic occur from ingestion 
of contaminated food and water. In the United States, the amount of arsenic in public 
drinking water is very highly regulated, and was recently reduced from 50 µg/L to 10 
µg/L by the EPA in 2001 based on its carcinogenicity (ATSDR, 2013). Besides cancer, 
arsenic has been linked to a number of diseases, including cardiovascular disease, type 2 
diabetes and immunological disorders (Mandal & Suzuki, 2002).  
When considering arsenic and type 2 diabetes, inflammation must be addressed. 
The inflammatory profile of a non-diabetic is very different from that of a diabetic 
individual, and arsenic as an immunotoxic agent can exacerbate this situation. Arsenic, 
has previously been found to modulate the overall immune profile in both lean and obese 
individuals by affecting gene expression, cell population and ROS production 
(Dangleben et al., 2013; Mandal & Suzuki, 2002; Tobergte & Curtis, 2013). However, in 
obese individuals, the systemic and local inflammatory profile contains more pro-
inflammatory components, such as M1 macrophages, whereas lean individuals will have 
a balance of M1 to M2 macrophages (Mosser & Edwards, 2008). Arsenic has been shown
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 to affect macrophages (Lemarie et al., 2006), therefore it could be suggested that arsenic 
would have different effects on the immune system in lean and obese individuals.  
In this study we proposed to examine the effects of sub-cytotoxic levels of arsenic 
on Raw 264.7 macrophages in both normal and high glucose environments, to represent 
non-diabetic and nondiabetic individuals, respectively. By varying glucose concentration, 
we were able to model the effects of arsenic in both normal and high blood glucose 
scenarios, similar to a normal and hyperglycemic individual and the stress that is put on 
the macrophages in each scenario. We evaluated gene expression changes in these 
macrophages by real-time PCR to determine whether they are more pro-inflammatory 
after an immune challenge following exposure to arsenic. We chose to evaluate these 
gene expression changes after either 3 or 24 hours of arsenic exposure to demonstrate 
differences in acute and chronic exposure, as arsenic has a half-life in the blood of 
approximately 3 hours (ATSDR, 2013) We hypothesized that arsenic exposure and 
higher concentrations of glucose will increase inflammatory cytokine expression in 
macrophages, especially over a period of chronic exposure. 
4.2 Methods 
4.2.1 Cell culture 
Raw 264.7 macrophages (ATCC) were grown to confluence in high or low 
glucose Dulbecco’s Modified Eagle Medium (DMEM, Hyclone) with 2% FBS (Hyclone) 
and 1% penicillin/streptomycin (ThermoFisher) at 37°C and 5% CO2. Cells were 
stimulated with lipopolysaccharide (Sigma-Aldrich) at 50ng/ml for 4 hours after exposure 
to inorganic arsenic (AsCl3 - Alfa Aesar,) in a serial dilution ranging from 1x10-7µM to 
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100µM for 3-24 hours to determine sub-cytotoxic concentrations to be used in future 
experiments 
4.2.2 Cell viability 
Cell viability was determined using CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay (Promega) according to manufacturer’s instructions. Cells were 
grown to confluence and then incubated with arsenic (0-100 µM) for 3 hours to 
determine sub-cytotoxic doses to be used in subsequent experiments.  
4.2.3 Gene expression 
RNA was isolated from cells using Isolate II kit (Bioline) according to 
manufacturer’s protocol with quantity and quality measured spectrophotometrically via 
260/280 ratio. Real-Time PCR was then performed using SensiFast 1-Step Sybr Green kit 
(Bioline) for PCR according to manufacturer’s protocol with 1ng RNA and 10 µM of 
designed and validated primers. Custom primers (Table 4.1) were designed for each 
target using Primer Blast Search (NCBI) and purchased from Integrated DNA 
Technologies (IDT) for qPCR. Gene expression patterns for each gene were normalized 
to the expression of the housekeeping gene RPLP0 and quantified using the ΔΔCT 
method. 
4.2.5 Statistics 
All statistical analyses were carried out using GraphPad Prism 7 Software (San 
Diego, CA). Results are expressed as the mean ± SEM, and all experiments were 
performed in triplicate to test reproducibility of results. Multiple comparisons were made 
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using one-way analysis of variance (ANOVA), followed by post hoc analysis using 
Tukey’s method. A p-value of <0.05 was considered statistically significant.  
4.3 Results 
4.3.1 Cell viability 
We wanted to establish sub-cytotoxic doses of arsenic to be used in the 
RAW264.7 macrophage experiments. The MTT assay (Figure 4.1), which determines cell 
viability colormetrically, demonstrated that any concentration greater than 0.1 µM had 
significantly reduced survival, as absorbance in the assay dropped from 2.74 to less than 
0.5. 
4.3.2. Three-hour arsenic exposure in low glucose 
Based on our hypothesis that sub-cytotoxic exposure to arsenic will modify 
cytokine gene expression in macrophages, we examined the changes in gene expression 
that occur at 3 hours of exposure in normal glucose concentrations. As arsenic 
concentrations increase from low (0.001µM) to high (0.01µM), there were no changes in 
cytokine expression in IL-10, TNF-α, STAT3 or TGF-β (Figure 4.2). These findings do 
not support our initial hypothesis that higher levels of arsenic exposure are enough to 
drive a pro-inflammatory response in macrophages. 
4.3.3. Three-hour arsenic exposure in high glucose 
In a diabetic state, as blood glucose increases we would expect the inflammatory 
state of macrophages to change from neutral to pro-inflammatory. Therefore, by adding 
in the inflammatory modulator of arsenic should cause a change in macrophage state, 
most likely pushing them toward a pro-inflammatory state. Here, we demonstrated that as 
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arsenic concentration increases, the expressions of IL-10 significantly decreased (Figure 
4.3).  These findings support our hypothesis of increasing arsenic exposure increases a 
pro-inflammatory response as IL-10 is an anti-inflammatory cytokine that inhibits Th1 
immune responses (Couper, Blount, & Riley, 2008). 
4.3.4. Twenty-four-hour arsenic exposure in low glucose 
We wanted to determine whether increasing the exposure time, similar to a more 
chronic level of arsenic exposure, would affect expression of cytokines by macrophages 
differently than short-term exposure. As expected, in low glucose, there was no 
significant changes in gene expression induced by arsenic exposure (Figure 4.4), 
demonstrated by no significant changes in gene expression in IL-10, TNF-α, STAT3 or 
TGF-β. This does not support our hypothesis that increasing the duration of arsenic 
exposure (acute vs chronic) would increase the expression of pro-inflammatory cytokines 
in macrophages.  
4.3.5. Twenty-four-hour arsenic exposure in high glucose 
 Finally, we wanted to determine the effects of chronic arsenic exposure on 
macrophages cultured in a high glucose environment, modeling a diabetic individual 
being exposed to the additional stressor of arsenic. After stimulation with LPS, we saw 
no significant changes in gene expression induced by arsenic exposure in IL-10, TNF-α, 
STAT3 or TGF-β (Figure 4.5), suggesting that chronic arsenic exposure does not induce 
inflammatory changes in macrophages. 
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Discussion 
 We expected to see changes in cytokine expression in macrophages exposed to 
arsenic as arsenic trioxide has been shown to increase TNF-α and IL-8 secretion and 
expression significantly in macrophages isolated from human peripheral blood 
mononuclear cells (PBMCs). (Lemarie et al., 2006). We found that the lower 
concentrations of arsenic had the greatest impact on macrophage cytokine expression, 
specifically IL-10, at 3 hours in high glucose. IL-10 is an anti-inflammatory cytokine, and 
an increase in production would result in diminished M1 and Th1 (pro-inflammatory) 
responses (Couper et al., 2008), resulting in a suppressed immune response. In high 
glucose conditions, both low and high arsenic concentrations lead to a reduction in IL-10 
expression, but this did not correlate with longer exposure, therefore supporting the 
possibility that acute arsenic exposure has a greater effect on immunity than chronic 
exposure Validation of increased protein secretion would solidify these results. Due to 
the importance of IL-10 in arsenic mediated macrophage changes, we also examined one 
of the downstream targets of IL-10, STAT3, as it is known transcription factor for anti-
inflammatory macrophages (Martinez & Gordon, 2014) While there was a slight decrease 
in expression at the highest arsenic concentration in the 3 hour high glucose treatment 
group, it was not significantly affected, suggesting while gene expression is increased,  
IL-10 protein in suspension may not be increased. However, this result could further be 
explained by examining protein concentration of IL-10, as well as additional upstream 
regulators targeting STAT3 such as IL-6, which is something we could explore in further 
studies (H. M. Wilson, 2014). Also affected in this treatment, although not significantly, 
was TGF-β. This is another anti-inflammatory cytokine, and with the combined decrease 
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in expression in TGF-β and IL-10, we would have expected to see an increase in TNF-α 
regulation, as TNF- α expression is negatively regulated by these cytokines. However, 
this was not the case in our model demonstrated by no change in TNF-α expression 
regardless of arsenic concentration, glucose concentration or time of exposure. 
 To gain better insight into the effects of arsenic exposure on M1 vs M2 
macrophages, we would have to first differentiate our cell culture toward one of these 
phenotypes prior to exposure. By doing so, we would be able to determine whether 
arsenic is in fact modulating the entire immune response (both pro and anti-
inflammatory) by having our cells already skewed toward a specific phenotype. It is 
interesting that the shorter arsenic exposure in high glucose appeared to have a greater 
effect on gene expression in macrophages. This could indicate that for human exposure to 
arsenic, the important changes to the immune system are more visible after acute 
exposure.  
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Table 4.1. Real time PCR Primer list.  
ID Forward 5’-3’ Reverse 5’-3’ 
TGF-β TTGCCCTCTACAACCAACACAA GGCTTGCGACCCACGTAGTA 
IL-10 TGGACTCCAGGACCTAGACA AGTGTGGCCAGCCTTAGAAT 
STAT3 TACCATTGACCTGCCGATGT TCCGAGGTCAGATCCATGTC 
TNF-α AGCACAGAAAGCATGATCCG CTACAGGCTTGTCACTCGAA 
RPLP0 CCTGAAGTGCTCGACATCAC GCGCTTGTACCCATTGATGA 
Abbreviations – Transforming growth factor beta – TGF-β, Interleukin 10 – IL-10, Signal 
transducer and activator of transcription 3 – STAT3, Tumor necrosis alpha – TNF-α, 
Ribosomal protein lateral stalk subunit P0 – RPLP0 
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Figure 4.1. Raw 264.7 macrophage cell viability after arsenic exposure. Raw 264.7 macrophage viability after 3 hours of inorganic 
arsenic exposure at concentrations ranging from 0-100µM. 
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Figure 4.2. Short term arsenic exposure has no effect on macrophage cytokine expression in low glucose environment. Raw 
264.7 macrophage gene expression after 3 hours of exposure in low glucose DMEM. mRNA levels are expressed relative to RPLP0. 
Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using ANOVA, followed by 
Tukey’s multiple comparison test.  
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Figure 4.3. Short term arsenic exposure suppresses macrophage IL-10 expression in high glucose environment. Raw 264.7 
macrophage gene expression after 3 hours of exposure in high glucose DMEM. mRNA levels are expressed relative to RPLP0. Data 
are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using ANOVA followed by Tukey’s 
multiple comparison test, and is indicated as * (p<0.05). 
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Figure 4.4. Long term arsenic exposure has no effect on macrophage cytokine expression in low glucose environment. Raw 
264.7 macrophage gene expression after 24 hours of exposure in low glucose DMEM. mRNA levels are expressed relative to RPLP0. 
Data are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using ANOVA followed by 
Tukey’s multiple comparison test, and is indicated as * (p<0.05). 
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Figure 4.5. Long term arsenic exposure has no effect on macrophage cytokine expression in high glucose. Raw 264.7 
macrophage gene expression after 24 hours of exposure in high glucose DMEM. mRNA levels are expressed relative to RPLP0. Data 
are represented as the mean of each treatment group ± SEM. Statistical significance was assessed using ANOVA followed by Tukey’s 
multiple comparison test. 
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Chapter 5 – Conclusions and Future Directions 
5.1 Baseline differences in genotype 
 In our research, we used two different mouse models (C57BL/6 and db/+) that are 
both representative of controls used in various diabetic experiments. Both are considered 
to be lean mice that do not develop type 2 diabetes under normal circumstances, but the 
C57BL/6 mouse will develop diabetes slowly when fed a high fat diet. In many studies 
that use the db/db mouse strain that become obese and diabetic around 4 weeks old, the 
db/+ mouse strain is the control. However, based on our study the C57BL/6 and db/+ 
mouse strains have several differences before the introduction of an environmental 
contaminant.  
The evaluation of body composition in our C57BL/6 vs db/+ mice show the db/+ 
mice gain weight at a faster rate than our wild-type in both males and females. This 
includes a higher body fat percentage in the females at 12 weeks of age and wild-type 
males had slightly higher lean mass compared to the db/+ genotype (Table 5.1). Either of 
these conditions would result in a change in the expected inflammatory profile (Table 5.2 
and Table 5.3). This was validated by male db/+ having slightly higher concentration of 
IL-13 in the spleen, and db/+ females having higher levels of IL-10 in spleen, TNF-α and 
IL-1β in serum. So at baseline, the male heterozygotes are already demonstrating a higher 
level of anti-inflammatory cytokines in circulation and females are more pro-
inflammatory. For the chosen cytokines analyzed by gene expression the wild-type and 
db/+ mice demonstrated no differences, but IL-13 was not among the chosen cytokines
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 The female db/+ mice exhibited a wide range of gene expression changes in 
adipose tissue and spleen that would point toward increased macrophage activity and 
inflammation. Female db/+ mice also had higher levels of triglycerides in all organs 
examined except for the liver (Table 5.4). There were no notable differences in males or 
females in glucose tolerance. 
Overall, besides body composition these mouse strains had varying differences in 
local and systemic inflammation and triglyceride levels. This makes them very different 
controls in experiments, so depending on the experiment certain changes may be 
magnified or lessened depending on the measured outcome. 
5.2 Effects of low dose arsenic on diabetes development 
 The development of diabetes in humans is complex, with only 1/3 of individuals 
that develop insulin resistance along with obesity will become diabetic (Donath & 
Shoelson, 2011). A family history may indicate future susceptibility to the disease, but 
this alone does not guarantee an individual will develop diabetes. It is a combination of 
factors that causes disease to occur. Our mouse models represented two different strains 
that are not susceptible to obesity or diabetes, which gives us information needed to infer 
ways in which the general public could respond to arsenic exposure. We observed that 
low-dose arsenic exposure alone is not enough to induce diabetes development, although 
it may cause slight changes in body composition and organ triglycerides (Table 5.5 and 
Table 5.6). It would be beneficial to continue this study in a diabetes-susceptible model to 
determine whether arsenic could impact the development of disease or shift disease onset, 
now that we have defined the baseline response. 
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 We found that low-dose arsenic exposure causes varying effects to the immune 
system that differ based on genotype and sex (Table 5.7 and Table 5.8). It was previously 
demonstrated in C57BL/6 male mice that exposure to arsenic at 100µg/L reduced 
immune response to influenza infection (Kozul, Ely, Enelow, & Hamilton, 2009). This 
differs from what we observed in our male C57BL/6 mice, which demonstrated 1-fold 
increase in circulating IFN-γ, IL-13 and IL-6 (Table 5.7).  
Depending on the tissue examined, expression of these cytokines varied greatly 
(Table 5.8). We chose to further determine what the effect of arsenic exposure on 
macrophages in vitro, as these immune cell types are particularly affected as obesity 
increases. We report here that at acute exposure in high glucose, arsenic significantly 
reduced IL-10, an important anti-inflammatory mediator. While we did not see an overall 
suppression of the macrophage cytokine response due to arsenic exposure, we can say 
that depending on the stress placed on the cells (i.e. higher glucose concentration), there 
will be a different immune response. This is important in the context of human exposures, 
as no two individuals will have the same baseline stress levels, supporting the idea that 
the effect of arsenic on the body will vary greatly from person to person. 
We originally hypothesized that arsenic exposure would decrease glucose 
tolerance in a non-susceptible mouse model, leading to an increase in type 2 diabetes 
susceptibility. Instead, we have demonstrated through these experiments that low-dose 
exposure to arsenic in a non-susceptible individual is not enough to drive diabetes, but it 
is enough to cause changes to the immune response. 
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Table 5.1. Summary of genotypic differences in body composition.  
Lines represent no change, or a fold change from control less than 1. One small arrows 
represent a fold change between 1-2 and 2 small arrows represent a fold change greater 
than 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lean Fat Total Fat % 
Males     
Females  
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Table 5.2. Summary of genotypic differences in systemic cytokines.  
 Spleen Serum 
TNF-α GMCSF IFN-γ IL-13 IL-10 IL-1β IL-4 IL-6 TNF-α IL-6 IL-1β 
Males            
Females            
Lines represent no change, or a fold change from control less than 1. One small arrows represent a fold change between 1-2 and 2 
small arrows represent a fold change greater than 2 
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Table 5.3. Summary of genotypic differences in immune-related gene expression.  
 Adipose Tissue Liver Spleen 
 Adiponectin Leptin 
TNF-
α 
Arginase iNOS CCL2 Arginase iNOS Arginase iNOS 
Males           
Females 
     
    
 
Lines represent no change, or a fold change from control less than 1. One small arrows 
represent a fold change between 1-2 and 2 small arrows represent a fold change greater 
than 2. 
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Table 5.4. Summary of genotypic differences in organ triglycerides 
 Muscle Kidney Liver Heart 
Males     
Females 
    
Lines represent no change, or a fold change from control less than 1. One small arrows 
represent a fold change between 1-2 and 2 small arrows represent a fold change greater than 2. 
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Table 5.5. Summary of arsenic effects on body composition.   
 
Lean Fat Total Fat % 
Male WT     
Male Het 
    
Female WT 
 
  
 
Female Het 
    
Lines represent no change, or a fold change from control less than 1. One small arrows 
represent a fold change between 1-2 and 2 small arrows represent a fold change greater 
than 2.  Light blue represents 1x arsenic exposure and dark blue represents 10x. 
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Table 5.6. Summary of arsenic effects on organ triglycerides.  
 Muscle Kidney Liver Heart 
Male WT 
 
 
  
Male Het 
  
  
Female WT 
    
Female Het 
    
Lines represent no change, or a fold change from control less than 1. One small arrows 
represent a fold change between 1-2 and 2 small arrows represent a fold change greater 
than 2. Light blue represents 1x arsenic exposure and dark blue represents 10x.
  
1
1
0
 
 Table 5.7. Summary of arsenic effects on cytokines.   
 Spleen Serum 
TNF-α GMCSF IFN-γ IL-13 IL-10 IL-1β IL-4 IL-6 TNF-α IL-6 IL-1β 
Male WT            
Male Het            
Female 
WT 
           
Female 
Het 
           
Lines represent no change, or a fold change from control less than 1. One small arrows represent a fold change between 1-2 and 2 
small arrows represent a fold change greater than 2. Light blue represents 1x arsenic exposure and dark blue represents 10x. 
 
 
 
 
  
  
1
1
1
 
Table 5.8. Summary of arsenic effects on immune-related gene expression.  
 Adipose Tissue Liver Spleen 
Adiponectin Leptin TNF-α Arginase iNOS CCL2 Arginase iNOS Arginase iNOS 
Male 
WT 
          
Male 
Het  
 
 
 
 
 
 
   
Female 
WT 
 
 
        
Female 
Het 
   
 
 
  
 
  
Lines represent no change, or a fold change from control less than 1. One small arrows represent a fold change between 1-2 and 2 
small arrows represent a fold change greater than 2. Light blue represents 1x arsenic exposure and dark blue represents 10x.
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